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Abstract 
 
There is an urgent need for the development of an effective therapeutic 
vaccine against cancer caused by human papilloma virus (HPV). I focused on 
HPV-induced malignancies because of their high worldwide prevalence (e.g., 
cervical carcinoma and head & neck cancer). A successful therapeutic vaccine 
could prevent the 250 000 deaths/year worldwide and the 2.25 billion dollars that 
are expended in related care in the US. 
We used an HPV-induced mouse cancer model to test vaccines 
composed of a CD8 T cell peptide epitope administered with potent adjuvants 
designed to generate vast numbers of high avidity cytotoxic T lymphocytes 
specific for the HPV16-E7 antigen. One vaccination strategy (TriVax) consists of 
intravenous administration of synthetic peptide HPV16-E749-57 administered 
together with a Poly-IC (a TLR3 agonist) and anti-CD40 monoclonal antibody 
(αCD40 mAb) while the second more simple strategy (BiVax) comprises solely of 
peptide plus Poly-IC. We used an E7 peptide as antigen in the vaccination 
strategies because expression of the viral E6 and E7 proteins is required to 
maintain oncogenic phenotype and because normal cells do not express E6/E7, 
therefore a therapeutic vaccine targeting these proteins has several advantages: 
a) a strong immune response can be induced since immune tolerance to these 
	   viii	  
foreign antigens does not exist and b) the strong immune response should not 
inflict damage to normal cells. 
TriVax and BiVax generate a high number of antigen specific CD8 T cells 
capable clear subcutaneous tumors and prevent recurrences; both vaccines are 
efficient through the i.v. and i.m. route. TriVax (prime-boost) clears tumor in 
100% of mice while BiVax clears tumor in 50% of mice, this differential effect is 
due to the number of antigen specific CD8 T cells and increasing the number of 
booster shot makes BiVax as immunogenic and efficient in clearing tumors. In 
the absence of type-I IFN signaling (in IFNαβR KO mice), TriVax is less effective 
in generating sufficient numbers of CD8 T cells that could be necessary for total 
disease eradication. We observed a significant anti-tumor effect of TriVax in the 
absence of interferon gamma (IFNγ), however the cytokine may play some role in 
the overall effectiveness of TriVax to completely reject the tumors. Immune 
responses produced by BiVax are highly dependent on the simultaneous 
administration of peptide and Poly-IC, on the peptide composition, vaccine 
formulation and route of administration. The magnitude of the response is 
dependent on the expression of the Poly-IC receptors TLR3 and melanoma 
differentiation-associated protein 5 (MDA5). Interestingly, the magnitude and 
duration of the CD8 T cell responses generated by peptide and Poly-IC mixtures 
does not rely on the presence of CD4 T cells, scavenger receptor-A (SR-A) or 
type-I IFN signals and was minimally affected by the absence of CD40 signaling. 
The present findings could facilitate the development of simple and effective 
subunit vaccines for diseases where CD8 T cells may hold a therapeutic benefit. 
 1 
 
 
Chapter 1: Introduction 
 
1.1 Overview 
According to Dr. Weinberg’s group the 8 hallmark of cancer include 
“sustained proliferative signaling, evading growth suppressors, resisting cell 
death, enabling replicative immortality, inducing angiogenesis, and activating 
invasion and metastasis, reprogramming of energy metabolism and evading 
immune destruction” [1]. In some cases viral infections can be directly linked to 
cancer, examples of these are Epstein-Barr virus (Hodgkin's, Burkitt's lymphoma, 
and nasopharyngeal carcinoma), hepatitis B virus (liver cancer), Hepatitis C virus 
(liver cancer), human T cell lymphotropic virus type 1 (adult T-cell 
leukemia/lymphoma), human herpesvirus 8 (Kaposi sarcoma / lymphoma), 
Merkel cell polyomavirus (Merkel cell carcinoma) and human papillomavirus 
(head and neck carcinoma, anal, vulvar, vaginal, penile and cervical cancer) [2-
9]. Amongst all these, cervical cancer (CC) stands out in importance because 
worldwide is the 2nd most prevalent cancer among women [10]. HPV causes 99% 
of cervical cancer worldwide and HPV-16 and -18 subtypes account for 80% 
those cases. There are 2 prophylactic vaccines that are used to prevent HPV 
infection but are not intended to treat neither established tumors, nor protect 
infected people from developing CC [11-13], and they do not protect against 
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infection with all oncogenic HPV genotypes. Furthermore, not all women have or 
will receive the vaccine and therefore are not protected from the development of 
CC [14]. Finally, conventional therapy for CC is ablative and associated with 10% 
recurrence; thus, there is an urgent need for the development of an effective 
therapeutic vaccine against cancer caused by HPV. A successful therapeutic 
vaccine could prevent the 250 000 deaths that occur every year in the US from 
this disease alone and the 2.25 billion dollars that are expended in related care in 
the US [15, 16].  
Immune-based therapies for cancer such as therapeutic vaccines may be 
an attractive alternative over radiation and chemotherapy for several reasons: 
Radiation and chemotherapy result is serious adverse effects and in many cases 
are not effective against large tumors or disseminated (metastatic) disease. On 
the other hand, a potential problem with immunotherapy is finding a good 
antigen. Since expression of the viral E6 and E7 proteins is required to maintain 
oncogenic phenotype and because normal cells do not express E6/E7, a 
therapeutic vaccine targeting these proteins has several advantages: (i) the 
tumor cell cannot lose their expression as an immune evasion mechanism; (ii) 
there is no immune tolerance generated against them and an effective immune 
response in not likely to generated autoimmunity that could compromise healthy 
cells. These benefits contrast with other vaccines that target tumor-associated 
antigens (TAA) that are also present in normal cells (e.g., melanoma, using 
tyrosinase as an antigen). Despite of this, immunotherapy for virus-induced 
cancer has not been successful in the clinic [17-22].  
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Our goal is to develop therapeutic peptide based vaccines against HPV 
induced cancers. The results of the work shown here indicate that the TriVax and 
BiVax strategies are appealing immunotherapeutic approaches for the treatment 
of established viral-induced tumors. We believe that these studies may help to 
launch more effective and less invasive therapeutic vaccines for HPV-mediated 
malignancies. 
In the following paragraphs I will discuss relevant aspects of HPV 
including their classification, structure, cycle, oncogenic proteins and the 
diseases caused by the virus. I will also address the nature of the immune 
response against HPV infection and neoplasia caused by the virus, the FDA 
approved prophylactic vaccines and currents approaches to the development of 
experimental therapeutic vaccines against HPV induced cancers, making an 
emphasis in our approach: peptide based vaccines. 
 
1.2 HPV  
Papillomaviruses (PVs) are highly species specific and can cause cancer 
in animals (non human primates, cattle, hamsters, sheep and dogs, among 
others [23-29]) and in humans [30]. The species infecting humans, HPV, has 
over 100 different genotypes worldwide, from these, types 6 and 11 are the most 
common cause of genital warts while genotypes 16 and 18 account for over 80% 
of the CC induced by HPV [31-35].  
Structurally, HPV is a double stranded DNA, non enveloped virus with 
icosahedral symmetry, the viral DNA is associated with proteins similar to 
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histones, wrapped in 72 capsomeres composed of two structural proteins, L1 and 
L2 [36, 37]. HPV’s genome is around 7900 bp long and is grouped into the Alpha, 
Beta, Gamma, Mu and Nu papillomavirus genera. The Alpha genus infects 
mucosa and skin and can be further classified in high risk (HR) and low risk (LR) 
types [38].  
 
1.2.1 High risk vs. low risk HPV types 
The classification of high and Low risk types is based on the ability of a 
particular HPV genotype to induce malignant transformation in humans. In fact, 
persistency of HR types is the single most important risk factor for the 
development of cancer [39-46]. HR genotypes include type 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 68, 73, 82, 23, 53 and 66, being types 16 and 18 the 
most common [47].  
The main differences between HR and LR genotypes are on the genes 
that encode the E6 and E7 proteins, which in turn impacts how efficient they are 
in malignant transformation. E6 and E7 genes from HR genotypes are very 
efficient in immortalizing primary genital keratinocytes and interacting with 
negative regulators of the cell cycle[42, 48, 49], thus allowing the persistency of 
episomal genomes in undifferentiated cells and productive replication of 
genomes or amplification in differentiated cells 41,47,48.  E7 from HR binds to 
retinoblastoma (Rb) tumor suppressor family of proteins with higher affinity (10 
fold) than LR, it also binds to Histone deacetylases 1 2 and 3 that are important 
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for activating cellular genes that contribute to stable viral genome [50]. The 
importance of these proteins is highlighted on the virus’s life cycle described 
below.  
 
1.2.2 HPV life cycle 
The life cycle of HPV is directly related to the cellular differentiation 
program of the host cell, establishing infection in the basal layer of the cervix 
where the stem cells (SC) reside and assembling the virons in the upper, 
terminally differentiated layers of the cervical epithelia. During the virus’s life 
cycle the order of expression of its proteins is highly regulated and follows the 
pattern showed below:  
First, HPV virions infect cells in the basal epithelial layer that become 
exposed through micro wounds or abrasions like those produced by sexual 
intercourse. Then, viral capsids bind to the basement membrane possible 
through integrin and heparin sulfate and/or laminin 5, the virions enter 
keratinocytes and the virus genome is replicated in the nucleus to about 100 
episomal copies per cell [51, 52]. Later, E1 binds to the HPV origin of replication 
prior to the initiation of DNA synthesis, E2 recruits E1 to the origin of replication 
and regulates the transcription of E6 and E7 from the early promoter and at some 
point the E2 gets disrupted leading to the deregulation of the E6 and E7 proteins. 
Deregulation of E6 and E7 leads to immortalization and cell transformation [53-
55]. E6 activities lead to dysregulation of organization, differentiation, and 
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chromosomal integrity of HPV infected epithelial cells, most importantly, HR E6 is 
able to bind the tumor suppressor protein, p53 and induces its rapid turnover by 
forming complexes with the E6AP ligase [56, 57]. Up-regulation of p53 leads to 
expression of Rb tumor suppressor family of proteins, HR E7 binds to and 
modulates Rb along with cell cycle regulatory proteins, leading to accelerated 
cellular and viral replication [58]. E7 also targets Rb for ubiquitin mediated 
degradation and induces abnormal centrosome number, genomic instability, 
chromosome misalignment and lagging chromosomes during mitosis [59]. At the 
same time that E6 and E7 are being up regulated, the E5 protein is being 
expressed and exerts an additive effect on the transforming properties of E6 and 
E7 [60]. Finally, the virion particles assemble in the outer layers of the epithelia 
cells that are terminally differentiated causing no inflammation, thus evading the 
immune system.  
 
1.2.3 HPV related disease 
HR HPVs genotypes cause virtually all of the CC worldwide and although 
most people infected never develop cancer, the high prevalence of HPV infection 
makes this disease one of the most common malignancy [41, 61, 62]. In fact CC 
is preceded only by breast cancer as the most common cause of death from 
cancer among women [63]. The cost of screening, follow up and treatment of CC 
approximates $6 billion dollars per year in the US alone [64].  
Risk factors for HPV induced cancers include smoking, long term oral 
contraceptive pill use, human immunodeficiency virus (HIV) co-infection, high 
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parity, HSV and chlamydia trachomatis infection, Phimosis, immune suppression 
as well as nutritional and dietary factors [65].  The interval from first infection to 
neoplasia has been estimated to be between 7-10 years. 
In addition to causing CC, HPV can cause penile, anal, and head and 
neck cancers. Head and neck cancer affects over 650 000 patients worldwide 
each year and 350 000 patients die from this disease, 30-65% of head and neck 
cancer are caused by HPV [66, 67]. Penile cancer is 10 times less common than 
CC and untreated patients usually die within 2 years of the diagnosis [68]. 
Finally, anal cancer with an incidence around 1.5% of all tumors of the digestive 
system is relatively uncommon with an estimated 690 related deaths annually 
[69-71].  
 
1.3 Natural immune response to HPV infection and CC 
1.3.1 Innate immune response to HPV infection and CC 
Cellular mediators of the innate immune responses to genital infection by 
HPV include Langerhans cells, macrophages and Natural Killer (NK) cells [72]. 
Macrophages negatively regulate the transcription of the E6 and E7 genes, and 
have antitumor effect against HPV transformed cells; their presence can be an 
indicator of the lesion regression [73]. In addition, a small number of NK cells 
have been observed in Condyloma acuminata, in mild to moderate dysplasias 
and in severe dysplasias, their activity is reduced in patients presenting stage I or 
II invasive CC [74]. 
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Cytokines are another important mediators of innate immune response to 
genital infection; indeed, malignant transformation involves loss of 
responsiveness to the inhibitory effects of some cytokines. Successful immune 
response against HPV infection is mediated by: the effects of Interferon gamma 
(IFNγ), Tumor growth factor β (TGFβ) and IFNα on infected cells [75-78]. IFNγ 
blocks the expression of the HPV 18 mRNA of CC cells, TGFβ inhibits 
proliferation of cells infected by HPV and IFNα has been shown to inhibit 
proliferation of HPV16 immortalized human keratinocytes at concentrations 10 to 
100 fold lower than those needed to inhibit growth of normal human 
keratinocytes [79-81]. 
 
1.3.2 Adaptive immune response to HPV infection and CC 
Both arms of the adaptive immune system, humoral and cellular, are 
involved in natural response to HPV infection. The humoral host’s immune 
response to HPV infection is directed to conformational epitopes of the L1 capsid 
protein, the antibodies produced are mainly of the IgG isotype, the response 
generated is usually slow, weak and varies considerably among women [82].  
Due to the intraepithelial nature of HPV infections, effective immune response 
against established infection and cancer is dependent on cellular immune 
response, in fact patients with persistent cell mediated immune defects are at 
increased risk of persistence of infection and development of HPV related cancer 
[83-86].  Notably, the most important mediator of cellular immune response to 
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HPV infection are CD4 T cells, predominance of CD4 cells favors regression, 
predominance of CD8 lymphocytes favors persistence and progression of the 
viral infection and cellular transformation. Indeed, The CD8-positive T cell 
infiltrate far exceeded the CD4-positive cells in the invasive, but not in the 
preinvasive lesions however they infiltrate the lesion diffusely which is likely the 
cause of their inefficiency in controlling the disease [87]. It is also possible that 
the number of the CD8 T cells generated during natural malignant progression is 
insufficient to control disease or that because progression to malignant lesion is 
usually slow, the CD8 T cells recruited are exhausted or are in other ways 
functionally impaired. Immunotherapy can generate a high number of antigen 
specific cells in a short period of time that could overcome these obstacles. 
 
1.3.3 Immune evasion mechanisms 
The life cycle of HPV itself acts as an immune evasion mechanism: (i) the 
expressions of viral proteins are kept to a minimum and are regulated spatially 
and temporally, (ii) there is no viremia, (iii) no lysis of infected cells, (iv) and HPV 
replication and assembly occur in cells already destined for death by anoikis 
therefore there is no induction of inflammation, which means the immune system 
does not receive danger signals, a stimuli that usually activates it.  
T cells need to see the antigen in the context of a HLA molecule and in the 
presence of co-stimulatory signals to be activated; the main host cells for HPV 
infection: keratinocytes, do not express HLA class II molecules and lack 
expression of co-stimulatory molecules; therefore, these cells are more 
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susceptible to a state of specific or anergic tolerance [87-89]. In addition, E7 from 
HR HPV can decrease the expression of HLA I molecules and Transporter 
associated with antigen processing (TAP) proteins, thus interfering with antigen 
presentation to CD8 T cells, resulting in down regulation of cellular immune 
responses, allowing HPV to persist in infected epithelial cells [90]. Likewise, the 
E5 protein is capable to interfere with antigen presentation by the enhancing the 
expression of gangliosides on cervical epithelial cells, which also inhibits 
cytotoxic CD8 T cells (CTL) function locally [91, 92]. 
Dendritic cells (DCs) are professional Antigen Presenting Cells (APCs) 
that set in motion a wide range of effector immune responses against pathogens. 
DCs are not activated by the uptake of HPV capsids constituting another evasion 
mechanism [93].  
Finally, HPV can evade the immune system by manipulating cytokine 
production. The IFN response to HPV infection, a key antiviral defense 
mechanism, is actively suppressed by the E6 and E7 proteins of the HR HPVs 
inhibiting the IFN receptor signaling pathways and the activation of the IFN 
response genes [94-96]. TNFα synthesis is also diminished in HPV infections, 
associated with a decrease in the expression of the CD80 co stimulatory 
molecule resulting in a decrease in the presentation capacity of Langerhans cells 
[97]. 
Peptide based vaccines can overcome these obstacles because the 
immune system is expose to HPV antigens required for malignant transformation 
but without the transforming capabilities and these antigens are given in 
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combination with immune adjuvants priming the immune system for a potent 
response directed specifically to antigens in the tumor cells. 
 
1.4 Prevention of genital neoplasia induced by HPV: Prophylactic vaccines 
There are two prophylactic vaccines approved by FDA for the prevention 
of HPV infection and the associated development of cervical intraepithelial 
neoplasia (CIN) 2/3 and vulvar intraepithelial neoplasia (VIN): Gardasil and 
Cervarix. Both vaccines are composed of virus like particles (VLP) these are very 
immunogenic self-assembling structures form of several subunits of the L1 
protein mixed with an adjuvant and administered i.m. over a six months period 
[98]. 
Gardasil (MERK) is a quadrivalent vaccine that uses the adjuvant 
amorphous aluminum hydroxyphosphate sulfate and it is directed against HPV 
types 16, 18, 6 and 11 although offers some cross protection against HPV types 
31, 33, 45, 52 and 58 [12, 99-101]. Seroconversion in 99-100% of vaccinated 
individuals is achieved 7 months after last immunization and the antibody titers 
remain stable for at least 5 years [102-104]. Gardasil has a 98% efficacy in 
preventing CIN 2/3, adenocarcinoma in situ and CC, 100% for VIN 2/3 [101]. 
Cervarix (GlaxoSmithKline) is a bivalent vaccine directed against HPV types 
16 and 18 and offers some cross protection against HPV types 31, 33 and 45 
[104-106]. In contrast to Gardasil the adjuvant used is AS04: Monophosphoryl 
lipid A (MPL) absorbed to aluminum hydroxide and the vaccine generates greater 
immune response and immune memory than Gardasil (titers 4-7 folds higher) 
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[107-109]. Cervarix efficacy is between 92-100% for the prevention of CIN2/3 
with a follow up protection of 8.4 years so far. 
Both prophylactic vaccines are very efficient in preventing infection by 
HPV through the generation of neutralizing antibodies, however these vaccines 
are not effective against established infection [11], established premalignant and 
malignant lesions and they do not protect against all oncogenic types. In addition, 
it is estimated that it would take more than 20 years to see an impact on cancer 
rates as a result of vaccination due to the long latency of HPV infection and the 
presence of already infected individuals [110]. Also, adherence to vaccination is 
suboptimal; in fact only 30% of the vaccinated individuals go through with the 3 
doses required of the vaccine. Finally, not all the individuals for whom the 
vaccine is recommended receive the vaccine (for ages 9 to 26) due most likely, 
in the case in young individuals, to cultural and parental consent issues. 
Therefore, there is an urgent need to develop therapeutic vaccines against 
established cancers caused by HPV.  
In the following paragraphs different approaches toward the development 
of experimental therapeutic vaccines against HPV induced cancer and the results 
of several clinical trials are highlighted  
 
1.5 Experimental therapeutic vaccines against HPV induced cancers  
Conventional therapies against genital diseases caused by HPV are 
mostly ablative and/or cytodestructive; these include cryotherapy, scissor 
excision, laser therapy and electrosurgery and although cryotherapy is often 
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highly effective in the short term with clearances of 70-80 % the rate of 
recurrence are quite high, around 25-39% and in some cases, like in multifocal 
lesions, physical removal of the affected tissue can be unpractical or futile [111-
114]. 
There is one therapeutic vaccine against cancers approved by the FDA: 
Provenge a DC based cancer vaccine supplemented with a cytokine (GM-CSF= 
granulocytes and monocytes colony stimulating factor) and tumor derived 
differentiation antigen (PAP= prostatic acid phosphatase) for the treatment of 
prostate cancer [115, 116]. There is no FDA approved therapeutic vaccine 
against HPV induced cancers. The reason immunotherapy is so attractive for the 
treatment of established cancers is that successful immunotherapy provides 
specific and long lasting immune response directed exclusively against the 
targeted antigen. As mention before our approach is the use of peptide vaccines, 
approaches used by others include DNA, vector, DC cells, protein and peptide 
based vaccines. The following paragraphs describe the most relevant aspects of 
each strategy, along with some of their advantages and disadvantages. 
 
1.5.1 DNA based cancer vaccines  
DNA vaccines are comprised of a bacterial plasmid, which utilizes a 
promoter that function in mammalian cells to drive expression of a gene encoding 
the protein of interest.  
Major advantages of DNA vaccines are their simplicity and overall safety, 
which translates to low production costs, overall stability, and ease of storage (no 
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refrigeration required) thus its large scale production and storage is cheaper and 
easier than protein based vaccines [117-119]. Because the DNA vaccines 
consist simply of a plasmid without other antigens, such as a viral or bacterial 
vector would have, no issues related to prior exposure to the pathogen arise 
[119]. 
One disadvantage of DNA based vaccine is their poor immunogenicity 
specially in humans, when compared with traditional protein based vaccines, due 
most likely to their inability to amplify and spread in vivo, there is also a small risk 
of integration to the genome [110]. Strategies to improve DNA vaccine potency 
include the use of more efficient promoters and codon optimization, addition of 
traditional or genetic adjuvants, electroporation, intradermal delivery and various 
prime-boost strategies [118]. Peng et al from Dr. Wu’s group used the vascular 
disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in conjunction 
with E7 DNA vaccination to generate potent antitumor effects in mice challenged 
with 1x105 TC-1 cells s.c. and vaccinated 10/13 and 16 days later with 
calreticulin/E7 DNA (CRT/E7). Although DMXAA treatment alone, CRT treatment 
alone and DMXAA/CRT induced anti tumor effect, mice treated with 
DMXAA/CRT/E7 had significantly smaller tumors [120]. Diniz et al used a DNA 
vaccine (pgD-E7E6E5) expressing the E7, E6, and E5 of HPV16 
genetically fused to the glycoprotein D of the HSV 1, which was 
administered to mice by the intradermal (i.d.) route using a gene gun to 
clear tumor in over 70% tumor free mice by day 20 after 2 boosters. In this study 
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mice were challenged with 5x105 TC-1 tumor cells and vaccinated 8 hours later 
followed by 2 boosters one week apart [121]. Wu A et al approach was to 
vaccinate mice with a DNA vaccine encoding Ii-PADRE linked to E6 (Ii-PADRE-
E6) 3 and 7 days after tumor challenge with 2x105 TC-1 cells obtaining the best 
therapeutic anti-tumor effects and best overall survival when compared to the 
other DNA construct tested (Ii-E6, E6, Ii-PADRE) [122]. Mohit et al vaccinated 
tumor-bearing mice (7 days after challenge with 1x105 TC-1 cells s.c.) with IP-10 
at the same inoculation site of TC-1 along with E7 protein fused to 
immunostimulatory molecule N terminal gp96 (E7-NT-gp96) delivery by PEI600-
Tat as non-viral gene delivery system. Following this strategy the author obtained 
significant suppression of tumor growth and improved overall survival [123]. 
 
1.5.2 Vector based cancer vaccines 
These strategies exploit the strong immune response generated by viral or 
bacterial components that function as adjuvant to enhance reactivity against 
cancer antigens. It is though that these strong immune responses are due to the 
targeting of DC and subsequent induction of inflammation, in fact several studies 
have shown that transgenes expressed by a viral vector are more immunogenic 
than antigen administered with adjuvant[118, 124, 125].  
The advantage of viral and bacterial vector vaccines is that they allow 
HPV epitopes to be delivered more efficiently to target cells and to induce 
endogenous synthesis of viral and recombinant proteins. Logistically, 
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recombinant viruses can be produced, administered, and quality controlled easier 
compared with other immunotherapy strategies. The disadvantage of some 
vectors is the development of host induced neutralizing antibodies to the vector 
itself, thus limiting its continued use [110]. Liao et al, developed a vesicular 
stomatitis virus (VSV) expressing the HPV16 E7 oncogene as a therapeutic 
vaccine against TC-1 mouse model of cancer. In this study mice were immunized 
with the viral vector vaccine 7 days after tumor challenge with 5x104 tumor cells 
s.c., 14 days after vaccination mice had tumors 10 fold smaller than mice 
vaccinated with empty vector [126]. Grasso et al, approach was to use an 
integrase defective lentiviral vector (IDLV) containing a non-oncogenic HPV16 E7 
protein fused to calreticulin (CRT). When mice were challenged with 2x105 TC-1 
s.c. and vaccinated 14 days later, 4/5 rejected tumor compared to 0/5 of the 
vector/GFP control group, using the same scheme but vaccinating when tumor 
were 3-4 mm diameter the authors achieved rejections in 1/8 treated mice [127]. 
Zhao et al, developed a bivalent recombinant vaccinia virus expressing modified 
E7E6 fusion proteins of HPV16 and 18 (rVVJ16/18E7E6) based on the vaccinia 
virus Tiantan strain. After challenging mice with 1 × 104 TC-1 cells at day 0 and 
then vaccinating them i.p. at day 1 and day 11 mice showed delayed tumor 
growth compared to non treatment or treatment with control vector group [128]. 
Sewell et al designed a bacterial vector vaccine by transforming an attenuated 
Listeria strain with an E7 expression cassette, which consisted of the HPV-16 E7 
sequence fused to the Listeria protein ActA (Lm-ActA-E7), with this strategy the 
authors obtained complete regression of HPV-positive tumors in 6 out of 8 mice 
 17 
tested. These mice were vaccinated 7 and 14 days after tumor challenge with 2 × 
105 TC-1 cells s.c [129]. 
 
1.5.3 DC based cancer vaccines 
The approval of Provenge by the FDA is a milestone in the 
immunotherapy field of DC vaccines, as mentioned before, in this approach, DCs 
are isolated from a cancer patient, loaded with antigens (peptides or even tumor 
cell lysates) ex vivo, activated and then reinfused into the patient through 
intradermal, subcutaneous, intravenous, or intranodal injections [130, 131]. To 
potentiate further the efficacy of DC vaccines these cells can be modified to 
upregulate the expression of costimulatory molecules, cytokines, chemokines, 
and anti apoptotic molecules, or down regulate the expression of inhibitory 
molecules [132]. One of the main drawbacks of DC based vaccines is that they 
require leukapheresis and cell culture processing of peripheral blood 
mononuclear cells (PBMCs), and thus a limited number of vaccinations can be 
used.  Several preclinical studies has been conducted using DC based vaccines, 
Kim et al for instance, used a DC pulsed with E7 peptide transfected with and 
anti-apoptotic siRNA targeting BIM; these treatment yield smaller size tumor as 
compared to no treatment when mice were immunized 3 days after s.c. 
inoculation of 5x105 TC-1 tumor cells, although no rejections were achieved 
[133]; the same group later showed using the same number of tumor cells and 
the same vaccination schedule, that by transfecting bone marrow DCs pulsed 
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with the E749-57 peptide with IL10 receptor siRNA (and effectively blocking IL10 
actions on the BM-DC) they could achieve tumor clearance in 80% of treated 
mice [134]. Yin et al, used DC loaded with the E749-57 peptide fused to the KDEL 
sequence, an endoplasmic reticulum (ER) retrieval signal, obtaining tumor 
clearance in 50% of mice challenged with 2x105 TC-1 cells s.c. and vaccinated 
10 days later [135]. Finally, Kang et al showed that vaccination mice inoculated 
with 2x104 TC-1 cells i.v. with DCs expressing an endosomal/lysosomal signal 
fused to the E7 peptide (Sig/E7/LAMP-1) yield a significantly lower number of 
pulmonary tumor nodules when compared to DC expressing the E7 peptide 
alone or no peptide at all [136]. However, despite the encouraging results of 
these and other preclinical studies, most clinical trials using DC based vaccines 
have failed to achieve satisfactory clinical results [132, 137-139].  
 
1.5.4 Protein-based cancer vaccines 
Major advantages of protein-based cancer vaccines is their ease of 
production, stability, safety profile and because they usually also contain both 
CD4 and CD8 epitopes and are processed by the host there is no concern about 
HLA restriction [110]. On the other hand purified proteins are inefficient in 
inducing CD8 T cell response because they are mostly processed through the 
MHC II pathway, which directs the immune response towards the Th2 phenotype 
if they are not coupled with the appropriate adjuvants, these vaccines tend to be 
more costly than peptide-based vaccines [140]. Sharma et al, used a chimeric 
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form of the 4-1BBL costimulatory molecule engineered with core streptavidin (25 
µg) plus modified E7 protein (50 µg) to effectively eradicating established tumors 
in approximately 70% of mice. In this study mice were inoculated with 1x105 TC-
1 cells s.c. and immunized 6 days later [141]. Wick et al on the other hand used 
Pentarix (100 µg) a recombinant protein-based vaccine directed at the E7 
proteins from HPV16, 18, 31, 45 and 52 plus Poly I:C (10 µg) or CpG 
oligonucleotide (10 µg) to cure mice challenged with 1x105 TC-1 tumor cells 
[142].  
 
1.5.5 Peptide-based cancer vaccines 
As mentioned before, our approach to the development of therapeutic 
vaccine against HPV induced cancer is the use synthetic peptides containing a 
CD8 T cells epitope of HPV 16 E7 protein to generate a large number of antigen-
specific CD8 T cells in a mouse model of cancer. Peptide vaccines offer the 
advantage of being safe, stable, easy to manufacture under good manufacturing 
practice (GMP) and therefore can readily be taken to the clinic. Peptides are not 
very immunogenic by themselves but their antigenicity can easily be improved by 
substituting amino acids at specific positions within the peptide sequence. 
 
Because small peptides that target CD8 T cells along can be poor 
immunogens, some investigators propose the use of long peptides (20 mer) that 
are somewhat longer than those that bind to MHC I (10-12 mer). These peptides 
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are thought to be more efficient at generating effector T cells, in the presence of 
immune adjuvants perhaps because some processing may be required [143]. 
Another approach is to link chemically multiple immunogenic epitopes to form 
stable linear complexes [144]. The major advantage of this approach is based on 
the easy chemical synthesis thus high purity of the manufactured peptides. 
Because CD4 T cell help is important to generate and sustain the MHC I 
restricted, CD8 T cell responses some researches use MHC II restricted epitopes 
derived from the same protein as the CD 8 T cell antigen in their vaccine 
preparation [144, 145]. 
Small peptides can be immunogenic if administrated with the appropriated 
adjuvants [146]. Different groups have tested several adjuvants for their ability to 
induce high, long lasting, antigen specific immune response against tumor 
antigens (Table 1 and [147]). There have been some encouraging results in 
mouse model of cancer, for example the group of Dr. Kast used four E7 peptides 
combined with the PADRE peptide and CpG plus ISA51 as adjuvants in a 
vaccine preparation called VacciMax ®, using these approach the group 
achieved eradication of 700mm3 tumors [148]. Dr. Guillen group used a 
combination of the E749-57 peptide, very small size proteoliposomes (VSSP) and 
incomplete Freund's adjuvant (IFA) to eradicate subcutaneous TC-1 tumors 
[149]. Dr. Wu’s group used the E749-57 and PADRE peptides and Poly I-C to 
generate to treat tumor-bearing mice; the combination of E7 peptide, PADRE and 
Poly I-C generated the highest immune response and better survival of tumor 
bearing mice compared to control mice. The group also evaluated the route of 
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immunization and found that Intra tumor immunization is superior to 
subcutaneous route, with higher tumor infiltrating lymphocytes (TILS) and E7 
specific CD8 T cells and better survival [150]. The results of both in preclinical 
(Table 1) and clinical studies (Table 2) show that peptide based vaccines are a 
viable approach to the treatment of established HPV induced cancers; however, 
as mentioned before, there is no FDA approved immunotherapy for these 
diseases. The results of my dissertation work shows that TriVax and BiVax are 
an appealing immunotherapeutic approaches for the treatment of established 
viral induced tumors. We believe that these studies may help to launch more 
effective and less invasive therapeutic vaccines for HPV mediated malignancies. 
In the following paragraphs ways of improving immunogenicity of peptide 
vaccines including the major characteristics of some of the most commonly 
studied adjuvant, stimulation of the CD40-CD40L pathway and blockage of 
immunosuppressive factors are highlighted.  
 
 22 
Table 1. Preclinical studies of peptide- based vaccines against HPV 
induced cancers: Mouse models. 
Vaccine Experimental design Major findings (related to therapeutic effects) 
E7 long peptide43-62 
10µg+ Poly I:C 
(vaccine) 10µg+ 
DMXAA 20µg/g of 
body weight 
- Subcutaneous model= 1x105 TC-1 
cells  
-Vaccination s.c.= D13 and D20 after 
tumor inoculation  
-DMXAA (i.p.) treatment= D20 after 
tumor inoculation 
- DC maturation= Vaccination s.c.= 
D0, D7 immunoassay= D14  
- Cervicovaginal tumor model=  
Intravaginal challenge TC-1= D0      
Vaccination s.c.= D4, D8              
DMXAA treatment= D8 
- DMXAA augmented immune response, anti tumor 
effect, DC maturation, and production of TNFα, IFNγ 
and IP-10 in the tumor effect of the DMXAA was 
dependent on time of administration  
- Introduction of novel aggressive cervicovaginal 
tumor model that recapitulates many aspect of CC 
tumor progression [151] 
E749-57 20µg+ PADRE 
20µg + Poly I:C 20µg 
Subcutaneous tumor model= 1x104 
TC-1 cells 
Inoculation of tumor cells= D0 
Vaccination s.c.= D3 and weekly until 
mice died or tumor reached 2 cm 
Intratumor vaccination= D3 and every 
5 days until mice died or tumor 
reached 2 cm 
- The combination of E7 peptide, PADRE and Poly 
I:C generates the highest immune response and 
better survival of tumor bearing mice. 
- Intra tumor immunization is superior to 
subcutaneous route, with higher TILS and E7 
specific CD8 T cells and better survival [150] 
E743-62 10µg+ CGN 
10µg 
Subcutaneous tumor model= 1x104 
TC-1 cells 
Tumor challenge= D0 
Vaccination s.c.= D4, D8, D12, D16 
- E7 peptide combined with CGN generates better 
immune responses in naïve mice, better anti tumor 
effect and improved survival 
- CGN mechanism of action is through TLR4 
- Co-administration of CGN may lead to enhance 
activation and migration of DCs to lymph nodes. 
- Other TLR4 ligands (Dextran, MPL A) produce 
comparable results to CGN [152] 
E749-57 50µg +SA-4-
1BBL 25µg 
Subcutaneous tumor model= 1x103 
TC-1 cells 
Tumor inoculation= D0 
Vaccination s.c.= D10 
- SA-4-1BBL has pleiotropic effects on DCs, T 
effector cells, and T regs 
- Co-administration of SA-4-1BBL lead to eradication 
of tumor in 75% of mice with long term immune 
memory, increase in memory CD8 pool (CD44high) 
- Co-administration of SA-4-1BBL restored tumor 
killing response in mice bearing bigger tumors 
- Co-administration of SA-4-1BBL was more efficient 
than MPL, LPS in eradicating tumor [153] 
E711-20 25µg + E782-90 
25µg + E786-93 25µg + 
E729-32 25µg + PADRE 
25µg + CpG ODN 
1826 50µg+ ISA51 
(VacciMax ®) 
Subcutaneous tumor model= 1x105 
TC-1/A2 cells 
Tumor inoculation in HLA 12mo old 
mice= D0 
Vaccination s.c.= D19 
- Eradication of 700mm3 tumors within 3 weeks after 
vaccination 
- Chemical linkage of antigen to PADRE was no 
necessary for vaccine success [148] 
E749-57 fused to 
PADRE 50µg+ CpG 
ODN 1826 50µg+IFA 
or ISA51 (VacciMax ®) 
Subcutaneous tumor model= 5x105 
C3 cells 
Tumor inoculation= D0 
Vaccination s.c.= D4, D5, D6, D9, 
D14 
- Eradication of D4 (9/10), D5 (10/10), D6 (9/10), D9 
27/30), D14 (5/5) old tumors 
- Some mice in the vaccine control group did not 
develop tumor [154] 
E749-57 50µg+ VSSP 
160µg (LPS 30µg/ml 
+ OMPC 20-
60µg/ml)+ IFA 
Subcutaneous tumor model= 2x105 
TC-1 cells 
Tumor inoculation= D0 
Vaccination s.c= D10, D24 
- Eradication of 100% of tumors by day 45 after 
tumor challenge 
- Better survival compared to peptide+ IFA (0% v.s. 
80%) 
- Higher numbers of antigen specific C8 T cells (2 
folds higher than with IFA) [149] 
E743-77 50µg +CpG 
ODN 1826 50µg 
Subcutaneous tumor model= 5x104 
TC-1 cells 
Tumor inoculation= D0 
Vaccination s.c.= D10, D14 
- Eradication of 8/10 tumors 
- Better anti tumor effect and survival compared to 
peptide plus IFA (0/10 vs. 8/10 tumor free mice) 
- Long peptide exerts better antitumor effect and 
survival than minimal epitope when combined with 
CpG 
- Activation of professional APC is necessary for 
generation of high numbers of antigen specific CD8 
T cells [155] 
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Table 2. Clinical studies of peptide- based vaccines against HPV induced 
cancers: Clinical trials 
Phase /  
Vaccine 
Experimental design Major findings  
Phase II   
Nine HPV16 E6 
and four HPV16 E7 
peptides, 0.3mg 
each+ Montanide 
ISA-51 
 
Objective= Test Immunogenicity and 
efficacy of a synthetic long-peptide 
vaccine in women with HPV16+ HGVIN 
N= 20 woman 
Vaccinations s.c. = 3-4 times, at 3 week 
intervals, each time in a different arm or 
leg 
 
At 3 months after the last vaccination: 
- 60%had clinical responses and reported relief of 
symptoms.  
- Complete regression of lesions= 5 women, no 
detectable HPV16 in 4 
At 12 months of follow-up: 
- Clinical responses= 79%, with a complete 
response in 47%, maintained at 24 months of 
follow-up.  
- All patients had vaccine-induced T-cell 
responses, patients with a complete response at 3 
months had a significantly stronger IFNγ 
associated proliferative CD4 T cell response and 
a broad response of IFNγ CD8 T cells than did 
patients without a complete response [143] 
Phase II / Long 
overlapping of 
HPV16 E6 and E7 
300µg+ Montanide 
ISA-51 
Objective= to evaluate the effect of 
HPV16 E6 and E7 synthetic long peptides 
vaccine on the antigen-specific T-cell 
response in resected CC patients 
N= 6 (4 completed, 2 no completed)  
Vaccination s.c.= 4 times at a 3 week 
intervals 
- T-cell responses= 6/6 (E6), 5/6 (E7)  
- Expansion of CD4 and CD8 T cells, detected up 
to 12 months after the last vaccination.  
- The vaccine-induced responses were dominated 
by effector type CD4(+)CD25(+)FOXP3(-) IFNγ 
producing T cells and CD4(+)CD25(+)FOXP3(+) T 
cells [156] 
Phase I / Nine 
HPV16 E6 +/- four 
E7 overlapping long 
peptides+ 
Montanide ISA-51 
Objective= to determine the toxicity, 
safety, and immunogenicity of HPV16 E6 
and E7 long peptide vaccine on end-stage 
cc patients. 
N= 35 
Vaccination s.c.= 4 times, at 3 week 
intervals.  
G1= 300mg/peptide 
G2= 100mg/E6 peptide+ 300 mg/E7 
peptide 
G3= separate injections of E6 and E7 
50mg/peptide. 
- No toxicity beyond grade 2  
- Co-injection of E6+E7 induced a strong and 
broad T-cell response dominated by immunity 
against E6 
- Injection of the E6 and E7 peptides at two 
different sites increased the E7 response but did 
not affect the magnitude of the E6-induced 
immune response [157] 
Phase I / E712-20 
(ascending doses)+ 
linker peptide 
(KSS)+ PADRE+ 
E786-93 5mg/ml+ 
Montanide ISA 51 
Objective= to test toxicity and tolerability, 
immune, virological and clinical response 
to the vaccine,  
N= 18 women with HGCIN or HGVIN 
HPV16+ and HLA-A2+ HPV16+ 
Vaccination s.c.= escalating doses: 207, 
617, and 2057µg/ml, 3 weeks apart. 
- 3/18 patients cleared dysplasia 
- 6/6 patients had an increased S100+ dendritic 
cell infiltrate 
- 10/16 patients had E7-specific immune 
responses   
- No DTH E712-20 in any patient  
- 12/18 patients cleared virus from cervical 
scrapings, but all biopsy had viral DNA 
- 6 partial regression CIN lesions [158] 
Phase I/II / E711-20+ 
E786-93+ PADRE+ 
Montanide ISA 51 
Objective= to determine clinical and 
immunologic parameters after vaccination 
N= 15 HLA-A*0201+ HPV16+ patients 
with recurrent or residual CC 
Vaccination s.c.= 4 times, at 3 week 
intervals in a dose escalation scheme: 
100µg, 300µg and 1,000µg of each 
peptide 
 
- No signs of toxicity 
- 2 patients had stable disease for more than 1 
year after vaccination 
- 3 patients died of the disease during or shortly 
after the vaccination period 
- 10 patients maintained progressive CC 
- No CTL against E7 peptide detected in any 
patient after vaccination  
- Strong PADRE helper peptide-specific 
proliferation was detected in 4/12 patients [159] 
Phase I / E786-93 
lipopeptide (4 
dosage groups: 0.1, 
0.3, 1.0, 2.0µM)  
Objective= to test the effectiveness of an 
HLA-A*0201-restricted, HPV-16 E7 
lipopeptide vaccine in eliciting cellular 
immune responses in vivo in women with 
refractory CC 
N= 12 
Vaccination s.c.= 4 times, at 3 week 
intervals 
- 4/10 patients had E786-93 specific CTLs before 
vaccination 
- 5/7 evaluable HLA-A*0201 patients after 2 
vaccinations 
- 2/3 evaluable HLA-A*0201 cultures after 4 
inoculations 
- 2/3 converted from unreactive to reactive after 
administration of 4 inoculations 
- No clinical responses or treatment toxicities [160] 
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1.6 Ways of improving immunogenicity of peptide vaccines 
1.6.1 TLRs as adjuvants 
The cells of the innate immune system can recognize structures that are 
present in pathogens but not expressed by mammalian cells this are called 
pathogen associated molecular patterns (PAMPs); the receptors capable to 
recognize these PAMPs are called pattern recognition receptors or PRRs. 
There are three classes of PRRs: Toll like receptors (TLRs), retinoic acid 
inducible gene I (RIG-I) like RNA helicases (RLHs: include RIG-I and MDA5), 
and nucleotide binding oligomerization domain (NOD)-like receptors (NLRs)[161]. 
TLRs are membrane bound PRRs located in the cytoplasmic and endosomal 
membranes, whereas RLHs and NLRs are localized to the cytoplasmic 
compartment [161]. 
TLRs allow the innate immune system to discriminate among different 
groups of pathogens, and because these receptors are expressed in cells of both 
the innate (DC, macrophages, NK cells and mast cells) and the adaptive immune 
system (antigen primed CD8 T cells), they serve as a bridge between these two 
arms or the immune system [162]. TLRs activate the nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB) pathway, which regulates cytokine 
expression, through several adaptor molecules including Myeloid differentiation 
primary response gene 88 (MyD88) and TIR-domain-containing adapter-inducing 
interferon β (TRIF). Activation of the NFκB pathway links innate and adaptive 
immune response by production of inflammatory cytokines such as IL1, IL6, IL8, 
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TNFα, IL12, chemokines and induction of costimulatory molecules such as 
CD80, CD86, and CD40.  
Some of commonly used TLR ligands employed as adjuvants in cancer 
immunotherapy include CpG (TLR9 ligand), LPS (TLR4 ligand) and Poly I:C 
(TLR3 ligand) among others. The following paragraphs offer a brief description of 
each of these TLR agonists. 
Unmethylated CG dinucleotides are present at high frequency in 
prokaryotic DNA but are rare in eukaryotic DNA and stimulate cells that express 
TLR 9 to mount an innate immune response characterized by the production of 
Th1 and proinflammatory cytokines improving the function of APCs and boosting 
the generation of humoral and cellular vaccine specific immune responses, 
maturation, differentiation and proliferation of NK cells, T cells, monocytes / 
macrophages and B cells [163-167]. Binding of CpG to TLR9 activates a 
signaling pathway that proceeds through the stimulation of MyD88, IL-1 
receptor-associated kinase (IRAK) and TNF receptor associated factor (TRAF) 
6 and subsequently, the recruitment of various MAP kinases and transcription 
factors (including NFκB, the activator protein 1 or AP-1 and Interferon regulatory 
factor 7) that up regulate the expression of pro inflammatory genes [168]. The net 
result is the stimulation of genes of the immune response (IL1α, IL1β, TLR9 and 
TNF), cell signaling (NFKB1A, MyD88, IRAK-M and A20) and cell movement 
(BCL2A1 BCL2-related protein A1, Nucleosome assembly protein 1, NAK and 
epidermal growth factor receptor) [169].  
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The effectiveness of CpG as adjuvant has been shown in pre clinical and 
clinical studies [170-176]. 
TLR4 activation by bacterial LPS is achieved by the coordinate and 
sequential action of three other proteins: LPS binding protein, CD14 and MD 2 
receptors, that bind LPS and present it to TLR4 by forming the activated (TLR4-
MD-2-LPS) 2 complex, this activation can cause an excessively potent host 
response that generates life-threatening syndromes such as acute sepsis and 
septic shock [177, 178]. For that reason some researchers prefer to use MPL a 
detoxified derivative of Salmonella minnesota lipid A, which has a strong safety 
profile while retaining the immunostimulatory properties of LPS [179]. MPL acts 
as a partial TLR4 agonist that is functionally biased to TRIF-related adaptor 
molecule (TRAM)/TRIF signaling pathway stimulating a protective immunity 
rather than activating a systemic inflammatory response and has been provided 
in several vaccine formulations, including AS01, AS02, and AS04 adjuvant 
systems [180-185]. Importantly, LPS causes up regulation of CD40 in human 
peripheral blood plasmacytoid DCs and myeloid DCs [186, 187]; the effects of 
the activation of the CD40-CD40L pathway are discussed below. 
 
1.6.1.1 Poly-IC (TLR3 Ligand) 
We use of Poly-IC in the vaccines formulation because previous studies in 
our lab show that among several TLR agonists, Poly-IC is the most effective in 
the generation of long lasting CD8 T cell response probably because Poly-IC is 
the most potent inducer of Type I IFN [147, 188]. Poly-IC is a dsRNA synthetic 
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analog that binds to TLR3 and induces DC maturation via the adaptor molecule 
Toll interleukin 1 receptor domain 1 (TICAM1) and can enhance immune 
response against tumors [189]. Poly-IC has already proven to be beneficial as a 
mucosal adjuvant for influenza virus vaccine in a murine infection model. It is 
recognized through TLR3; in fact, TLR3 deficient mice showed reduced 
responses to Poly-IC and reduced production of inflammatory cytokines. Poly-IC 
has been used in the experimental treatment of melanoma, hepatoma, CC, 
breast, colon, urinary tract tumors, prostate cancer and hematopoietic tumors 
[190]. Interestingly, many tumor cells and tissues have elevated expression of 
some TLRs; TLR3 is expressed in Melanoma, breast cancer, colon cancer and 
Hepatocellular carcinoma. Zitvogel et al, found TLR3 positive tumor cells in 10% 
of patient samples and these cells responded well to Poly-IC treatment probably 
by inducing apoptosis [191]. 
In addition to TLR3, the RLHs RIG I and MDA5 may also act as sensors of 
viral infections through recognition of viral dsRNA and might up regulate Type I 
IFNs; MDA5 preferentially recognizes high molecular weight Poly-IC fragments 
while RIG I shows a preference for shorter RNA fragments and can also bind to 
ssRNA and recognizes paramyxoviruses, influenza virus and Japanese 
encephalitis virus [192, 193]. RIG I encodes a DExD/H box RNA helicase 
containing a caspase recruitment domain, the caspase recruitment domain 
transmits ‘downstream’ signals through the caspase recruiting domain containing 
IFNβ promoter stimulator (Cardif), resulting in the activation of the transcription 
factors NFκB and IRF-3 [194]. 
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1.6.2 Targeting the CD40-CD40L pathway 
We use an agonist αCD40 mAb in the formulation of one of our vaccines 
(TriVax) because CD40-CD40L interactions are important for the priming of CD8 
T cell by APCs and DC maturation. CD4 T cells, which express CD40L, interact 
with DCs, which express CD40, and as a result the DCs become activated and 
are able to stimulate CD8 T cells. CD40-CD40L interactions up regulate the 
production of IL7, 12, and 15 on human mDCs, which contributes to CD8 T cell 
antigen specific expansion; thus, αCD40 mAb can directly activate APCs without 
the need of CD4 T cells and turn them into potent stimulators for CD8 T cells 
[195-198].  In addition to DCs, the activation of macrophages and NK cells 
appears to contribute to the in vivo antitumor effects of CD40 agonists [199, 200]. 
Several clinical trials using CD40 directed therapies for human cancers have 
been published and antibodies against CD40 have already been used as a 
therapeutic choice in an experimental model of autoimmune encephalitis, 
representing multiple sclerosis or in efforts to block atherosclerosis [201-208]. 
CD40 agonists have also been used to reinforce immune defense against tumors 
through CD40 system mediated pathways and CD40 ligation can overcome 
peptide induced peripheral CTL tolerance and increase antitumor vaccine 
efficacy [209-211].  
C40-CD40L interaction stimulates the synthesis of many cytokines and 
adhesion molecules including IL1, IL2, IL6, IL8, IL10, TNFα, IFN, lymphotoxin A, 
TGFβ, GM-CSF and chemokines [212]. CD40 stimulation on endothelial cells up 
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regulates the expression of vascular cell adhesion protein 1 (VCAM1), 
intracellular adhesion molecule 1 (ICAM1) and E-selectin which facilitates 
lymphocyte attachment, rolling and transmigration into the inflamed site; as a 
result, CD40 mediated signaling may be crucial in promoting the migration of 
tumor reactive immune effector cells into the tumor tissue [213]. 
CD40 activation can induce the function of various downstream signaling 
pathways including both, pro apoptotic and anti apoptotic proteins. Indeed, 
signaling via CD40 may reactivate the antigen presenting functions of malignant 
cells and partly restore their in vitro recognition and killing by CTLs by 
upregulating the surface expression of ICAM1, MHC I, TAPs and tapasin, CD70, 
B7.1 and B7.2 and Fas and inducing immunostimulatory cytokine production on 
these cells [214, 215].  In contrast, CD40 expression in a wide variety of human 
cancers directly influence malignant cell proliferation and survival through the up-
regulation of pro apoptotic gene products such as Bax and Fas, and the 
progressive loss of the survival protein cellular FLICE/caspase-8-inhibitory 
protein (cFLIP) protecting them from apoptosis [216-226]. 
 
1.6.3 Blockade of inhibitory/suppressor factors 
Another way to improve immunogenicity of peptide vaccines is to 
administer (in addition to adjuvants) reagents that block inhibitory or suppressive 
factors either systemically or in the tumor microenvironment. To do so some 
researches use reagents capable of blocking the programmed death 1/ 
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programmed cell death 1 ligand 1 (PD-1/PD-L1) pathway, the cytotoxic T 
lymphocyte antigen 4 (CTLA4) signaling or Treg’s suppressive effect 
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Chapter 2: TriVax-HPV: An Improved Peptide-Based Therapeutic 
Vaccination Strategy Against Human Papillomavirus-Induced Cancers1. 
 
2.1  Abstract 
Background: Therapeutic vaccines for cancer are an attractive alternative 
to conventional therapies, since the later result in serious adverse effects and in 
most cases are not effective against advanced disease. HPV is responsible for 
several malignancies such as cervical carcinoma. Vaccines targeting oncogenic 
viral proteins like HPV16-E6 and HPV16-E7 are ideal candidates to elicit strong 
immune responses without generating autoimmunity because: (1) these products 
are not expressed in normal cells and (2) their expression is required to maintain 
the malignant phenotype. Our group has developed peptide vaccination strategy 
called TriVax, which is effective in generating vast numbers of antigen-specific T 
cells in mice capable of persisting for long time periods.  
Materials and methods: We have used two HPV-induced mouse cancer 
models (TC-1 and C3.43) to evaluate the immunogenicity and therapeutic  
 
                                                
1 Portions of these results have been previously published [227] and are utilized with permission 
of the publisher. 
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efficacy of TriVax prepared with the immunodominant CD8 T-cell epitope HPV16-
E749-57, mixed with Poly-IC adjuvant and costimulatory αCD40 antibodies.  
Results: TriVax using HPV16-E749-57 induced large and persistent T-cell 
responses that were therapeutically effective against established HPV16-E7 
expressing tumors. In most cases, TriVax was successful in attaining complete 
rejections of 6-11-day established tumors. In addition, TriVax induced long-term 
immunological memory, which prevented tumor recurrences. The anti-tumor 
effects of TriVax were independent of NK and CD4 T cells and, surprisingly, did 
not rely to a great extent on type-I or type-II interferon.  
Conclusions: These findings indicate that the TriVax strategy is an 
appealing immunotherapeutic approach for the treatment of established viral-
induced tumors. We believe that these studies may help to launch more effective 
and less invasive therapeutic vaccines for HPV-mediated malignancies [227]. 
 
2.2 Introduction 
Cervical cancer is the second most prevalent cancer among women. HPV 
causes 99 % CC, and the HPV16 and HPV18 genotypes account for 80 % these 
cases [228]. Worldwide, CC is responsible for ≈ 250 000 deaths per year and for 
causing a huge economic burden in related health care costs [64, 229]. The 
current approved prophylactic vaccines for HPV are not useful for treating 
established malignant disease, nor can protect already infected individuals from 
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developing cancer [11-13]. Most importantly, a significant proportion of women, 
especially in the third world, will not receive the prophylactic vaccines and will 
continue to be at high risk of developing CC [230]. Because, conventional 
therapies for CC are usually devastating, invasive, toxic, and associated with 10 
% recurrence [231], there is an urgent need for developing alternative treatments 
such as immunotherapy and, more specifically, therapeutic vaccines. 
CD8 T lymphocytes are the most effective components of the adaptive 
immune system capable of recognizing and destroying viral-infected and 
transformed malignant cells [232-234]. The antigens recognized by CD8 T cells 
on their target cells are small peptides derived from viral or TAAs that associate 
with cell surface class I products of the MHC-I. In the case of cells transformed 
by HPV, peptide sequences derived from the oncogenic E6 and E7 viral proteins 
have been shown to represent suitable TAAs for CC and are considered as ideal 
candidates for developing therapeutic vaccines [143, 148, 150, 151, 235-237]. 
Synthetic peptides representing these TAAs have been tested in numerous ways 
in patients and mouse cancer models for their ability to generate anti-tumor T-cell 
responses capable of exhibiting anti-tumor effects [148, 150, 235, 238-240]. 
However, in most instances, only modest T-cell responses capable of dealing 
with very early disease stages were obtained, indicating that improved peptide-
based immunization strategies need to be developed to have a significant impact 
against established and advanced disease stages. 
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Our laboratory has recently described an improved peptide vaccination 
strategy capable of generating in mice vast numbers of CD8 T cells capable of 
persisting for long time periods [147, 241]. This vaccine called TriVax consists of 
a synthetic peptide corresponding to the minimal T-cell epitope, Poly-IC adjuvant, 
and costimulatory monoclonal αCD40 mAb, which are mixed together and 
administered intravenously. After two sequential TriVax immunizations 
(prime/boost) with the well-known Ova257-264 T-cell epitope, up to 80 % of all the 
CD8 T cells in blood were antigen specific, and more than half of these cells 
persisted for at least 60 days [147]. The goal of the present study was to 
evaluate the efficacy of TriVax in an HPV cancer mouse model. The results 
demonstrate that TriVax using peptide HPV16-E749-57 induced large and 
persistent T-cell responses that were effective against two different tumors 
expressing HPV16-E7. Interestingly, the anti-tumor effects of TriVax in this tumor 
model appeared to be independent of NK and CD4 T cells and did not rely to a 
great extent on either type-I or -II interferons. We believe that the results from 
these studies may help to develop more effective therapeutic vaccines for CC. 
 
2.3  Material and Methods 
2.3.1 Mice 
Six to nine week old female C57BL/6 (B6) mice were obtained from the 
National Cancer Institute/Charles River program (Wilmington, MA). 
 35 
IFNγ knockout (KO) mice in the B6 background were purchased from Jackson 
Laboratories (Bar Harbor, ME). IFNαβ receptor KO (IFNαβR KO) mice also in the 
B6 background were obtained from Dr. Philippa Marrack (National Jewish 
Medical and Research Center, Denver, CO). All animal care and experiments 
were conducted according to our institutional animal care and use committee 
guidelines. 
 
2.3.2 Cell lines 
TC-1 tumor cells, obtained from Dr. T-C Wu (Johns Hopkins University, 
Baltimore, MD), were derived from primary lung epithelial cells of B6 mice and 
express HPV16 E6 and E7 proteins [242]. The C3.43 tumor cell line obtained 
from Dr. W. M. Kast (University of Southern California, Los Angeles, CA) is an 
aggressive derivative of the C3 line (B6 background), which was transformed 
using a pRSV- neo-derived plasmid containing the complete HPV16 genome 
[238]. The EL4 cell line was purchased from the American Type Culture 
Collection (Manassas, VA).  
 
2.3.3 Peptides, MHC-I tetramer, and antibodies 
The synthetic peptide RAHYNIVTF from HPV16 E7 (E749-57), defined as 
an immunodominant H-2Db-restricted CD8 T- cell epitope [238, 243], and control 
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peptide NAYVFKGL from chicken ovalbumin (Ova176-183) were purchased as >95 
% pure from A&A Labs (San Diego, CA). Rat anti-mouse CD40 (FGK45.5) anti-
NK1.1 (PK136), anti-CD4 (GK1.5), and anti-CD8 (2.43) monoclonal antibodies 
were prepared from hybridoma culture supernatants. The E749-57/H-2Db 
tetramers labeled with Alexa 647 were provided by the National Institute of 
Allergy and Infectious Disease Tetramer Facility at the Emory University (Atlanta, 
GA from NIH). Fluorochrome-labeled antibodies specific for mouse CD8a (53-
6.7) and MHC II (M5/114.15.2) were from eBioscience, Inc (San Diego, CA). 
 
2.3.4 Immunizations 
Mice were usually vaccinated via the i.v. route (unless otherwise noted). 
TriVax consisted of a mixture of 30 µg of the E749-57 peptide, 100 µg of αCD40 
mAb, and 50 µg of Poly-IC (Poly-ICLC, Oncovir, Inc.). BiVax contained only the 
peptide and Poly-IC at the same amounts. In all cases, mice are given two 
sequential vaccinations 13 days apart (prime and boost). In some cases, mice 
received peptide alone or peptide with αCD40 mAb. 
 
2.3.5 Immunological assays 
For tetramer staining, either peripheral blood samples (≈3-5 drops) taken 
from the submandibular vein or splenocytes were stained with a mixture of 
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antibodies to MHC II, CD8a (eBioscience; San Diego, CA), and tetramer for 40 
min in ice. After washing with three times, the Fluorescence was evaluated using 
an LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo software 
(Ashland, OR). Results are presented as percentage tetramer positive cells of 
the CD8+/MHC II negative population. To determine whether CD8 T cells were 
able to recognize tumor cell lines (TC-1, C3.43) expressing the naturally 
processed peptide, IFNγ, enzyme linked immunosorbent spot (EliSpot) assays 
were performed as described [244]. Briefly, CD8 T cells from spleens of 
vaccinated mice were purified by positive selection using antibody-coated 
magnetic beads (Miltenyi Biotec, Auburn, CA). Responder (CD8-purified) cells 
were incubated at 3x105, 1x105, and 3x104 per well, together with 1x105 
stimulator cells (EL4, plus/minus peptide, TC- 1, and C3.43 cells pretreated or 
not for 24 h with 100 ng/ml IFNγ). Cultures were incubated at 37 °C for 20 h, and 
spots (IFNγ producing cells) were developed as described by the EliSpot kit 
manufacturer (Mabtech, Inc., Mariemont, OH). Spot counting was done with an 
AID EliSpot Reader System (Autoimmun Diagnostika GmbH, Strassberg, 
Germany). 
 
2.3.6 Evaluation of therapeutic anti-tumor effects 
Mice received 3x105/mouse tumor cells (TC-1 or C3.43) s.c. in a shaved 
rear flank 6 or 11 days (as noted) before their first immunization. In some 
instances, survivor mice were re-challenged with the same number of tumor cells 
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(in opposite flanks). To determine the contribution of different subsets of 
lymphocytes, the anti-tumor effect of the vaccine, NK, CD4, and CD8 cell 
antibody-depleted mice and KO mice was compared with B6 wild-type (WT) 
mice. For cell depletions, each mouse received 300 µg anti-NK1.1, 300 µg anti-
CD4, or 500 µg αCD8 twice on days -2 and 0 before immunization. Depletions 
were confirmed by analysis of blood samples using flow cytometry (data not 
presented). Tumor growth was monitored every 2-4 days in individual tagged 
mice by measuring 2 opposing diameters with a set of calipers. Mice were killed 
when the tumor area reached 400 mm2. Results are presented as the mean 
tumor size (area in mm2) ± SD for every treatment group at various time points 
until the termination of the experiment. 
 
2.3.7 Statistical analyses 
Statistical significance of the numbers of antigen specific CD8 T cells 
(EliSpot) using unpaired Student’s t tests. Tumor sizes between 2 populations 
throughout time were analyzed for significance using 2-way ANOVA tests. All 
analysis and graphics were done using GraphPad Prism 5.01 (GraphPad 
Software, San Diego, CA). 
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2.4  Results 
2.4.1 Evaluation of TriVax immunization using a peptide epitope from 
HPV16-E7 
Residues 49-57 of the HPV16-E7 protein (RAHYNIVTF) correspond an 
immunodominant CD8 T cell epitope restricted by the H-2Db MHC-I molecule 
[238, 243]. We first determined the ability of synthetic peptide E749-57 
representing this sequence to elicit an immune response when administered to 
mice in combination with Poly-IC and αCD40 mAb, a vaccine formulation known 
as TriVax. In addition, we compared the immunogenicity of vaccines containing 
peptide alone, peptide plus Poly-IC (BiVax), or peptide plus αCD40 mAb. 
Antigen-specific immune responses were measured using tetramer 
analysis six days after the prime and booster immunizations and at various time 
points thereafter. As shown in Fig. 1a, TriVax and BiVax induced very high 
number of antigen-specific (tetramer positive) CD8 T cells after the booster 
immunization, which persisted at high levels for several weeks (Fig. 1b). On the 
other hand, administration of the E749-57 peptide alone or in combination with 
αCD40 mAb failed to generate a significant immune response. More importantly, 
spleen CD8 T cells from TriVax- and BiVax-immunized mice were shown to be 
very effective in recognizing E749-57 peptide-pulsed target cells (EL4) and TC-1 
tumor cells, which express the HPV16-E7 protein and naturally process the 
antigen (Fig. 1c). 
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spleen CD8 T cells from TriVax- and BiVax-immunized
mice were shown to be very eVective in recognizing E749-57
peptide-pulsed target cells (EL4) and TC-1 tumor cells,
which express the HPV16-E7 protein and naturally process
the antigen (Fig. 1c).
Anti-tumor eVectiveness of TriVax
The therapeutic anti-tumor eVects of the 4 modes of peptide
vaccination were assessed. Mice bearing 6-day established
TC-1 tumors received the peptide vaccines (prime/boost),
and tumor sizes and immune responses were measured at
various time points. As shown on Fig. 2a, tumor growth
was eVectively controlled in those mice that received
TriVax, BiVax, and, to some extent, peptide E749-57 with
!CD40 mAb, as compared to mice vaccinated with E749-57
alone (where tumors grew at an accelerated rate and mice
had to be euthanatized by day 22). Notably, 100 % of the
mice that received TriVax and 33 % of those receiving
BiVax completely rejected their tumors, while in the case
of the mice immunized with E749-57 with !CD40 mAb,
although the tumors grew at a slow rate, none were
rejected. Measurements of the immune responses elicited
by these vaccines in the tumor-bearing mice (Fig. 2b)
Fig. 1 Synergy for the potentiation of the immunogenicity of E749-57
peptide by poly-IC and !CD40 mAb. a Frequencies of antigen-speciWc
CD8 T cells in blood measured by tetramer analysis 6 days after prime
and boost induced by immunization using various vaccine formula-
tions. Numbers below the oval gates represent the % of tetramer-posi-
tive cells of the CD8-positive population. Dot plots showing the
percentage of tetramer-positive cells in blood of a mouse from each
group (3 mice/group). b Average percentage of tetramer-positive cells
in the blood of mice in each group measured at diVerent time points
(same experiment as in a). c Separate experiment where CD8 T cells
were puriWed from pooled splenocytes 7 days after the boost and anti-
gen-induced responses to various target cells was evaluated using IFN"
EliSpot assays. Stimulator cells: EL4 cells pulsed or not with E749-57
peptide and TC-1 cells (expressing HPV16-E7) were used to evaluate
CD8 T-cell responses from TriVax- (top row) and BiVax (bottom
row)-vaccinated mice. In this experiment, each well contained 1 £ 104
CD8 T cells and 1 £ 105 stimulator cells. Numbers represent the total
spots present in each well. Representative results of data obtained from
two diVerent experiments
 
Fig. 1 Synergy for the potentiation of the immunogenicity of E749-57 peptide by Poly-IC and αCD40 
mAb.  (a) Frequencies of antigen specific CD8 T cells in blood measured by tetramer analysis 6 
days after prime and boost induced by immunization using various vaccine formulations. 
Numbers below the oval gates represent the % of tetramer positive cells of the CD8 positive 
population. Dot plots showing the percentage of tetramer positive cells in blood of a mouse from 
ach gr up (3 mice/group).  (b) Average percentage of tetram r positive cells in th  blood of mice 
in each group measured at different time points (same experiment as in panel a). (c) Separate 
ex eriment where CD8 T cells w re purified from po led splenocytes 7 days after th  boost and 
antigen-induced responses to various target cells was evaluat d using IFNγ EliSpot assays. 
Stimulator cells: EL4 c lls pulsed or not with E749-57 peptide and TC-1 cells (expressing HPV16-
E7) were used to evaluate CD8 T cell responses from TriVax (top row) and BiVax (bottom row) 
vaccinated mice. In this experiment each well contained 1x104 CD8 T cells and 1x105 stimulator 
cells. Numbers represent the total spots present in each well. Representative results of data 
obtained from two different experiments. 
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2.4.2 Anti-tumor effectiveness of TriVax 
The therapeutic anti-tumor effects of the 4 modes of peptide vaccination 
were assessed. Mice bearing 6-day established TC-1 tumors received the 
peptide vaccines (prime/boost), and tumor sizes and immune responses were 
measured at various time points. As shown on Fig. 2a, tumor growth was 
effectively controlled in those mice that received TriVax, BiVax, and, to some 
extent, peptide E749-57 with αCD40 mAb, as compared to mice vaccinated with 
E749-57 alone (where tumors grew at an accelerated rate and mice had to be 
euthanatized by day 22). Notably, 100 % of the mice that received TriVax and 33 
% of those receiving BiVax completely rejected their tumors, while in the case of 
the mice immunized with E749-57 with αCD40 mAb, although the tumors grew at a 
slow rate, none were rejected. Measurements of the immune responses elicited 
by these vaccines in the tumor-bearing mice (Fig. 2b) indicated that both TriVax 
and BiVax induced high numbers of persisting E749-57-specific CD8 T cells. 
Interestingly, the differences between TriVax and BiVax were less apparent as 
compared to those observed in tumor-free mice (Fig. 1b). E749-57 with αCD40 
mAb induced a small CD8 T- cell response (between 3 and 5 % tetramer-positive 
cells), but apparently strong enough to reduce the tumor growth. No appreciable 
immune response was observed in mice that received E749-57 alone. The 
therapeutic effect of TriVax with E749-57 was antigen specific since TriVax 
prepared with an irrelevant peptide (Ova176-183) was not effective in reducing the 
rate of tumor growth (Fig. 2c). The therapeutic effects observed with E749-57 
BiVax (Fig. 2a) were confirmed in an additional experiment using a larger number 
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of mice (6), where in this case, this therapeutic vaccination strategy resulted in 
50% complete tumor rejections (Fig. 2d). Moreover, when BiVax was 
administered three times (prime plus 2 boosts, 7 days apart), rejections were 
observed in 100 % of the mice (data not presented). 
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indicated that both TriVax and BiVax induced high num-
bers of persisting E749-57-speciWc CD8 T cells. Interest-
ingly, the diVerences between TriVax and BiVax were less
apparent as compared to those observed in tumor-free mice
(Fig. 1b). E749-57 with !CD40 mAb induced a small CD8 T-
cell response (between 3 and 5 % tetramer-positive cells),
but apparently strong enough to reduce the tumor growth.
No appreciable immune response was observed in mice that
received E749-57 alone. The therapeutic eVect of TriVax
with E749-57 was antigen speciWc since TriVax prepared
with an irrelevant peptide (Ova176-183) was not eVective in
reducing the rate of tumor growth (Fig. 2c). The therapeutic
eVects observed with E749-57 BiVax (Fig. 2a) were con-
Wrmed in an additional experiment using a larger number of
mice (6), where in this case, this therapeutic vaccination
strategy resulted in 50 % complete tumor rejections
(Fig. 2d). Moreover, when BiVax was administered three
times (prime plus 2 boosts, 7 days apart), rejections were
observed in 100 % of the mice (data not presented).
The impressive therapeutic anti-tumor eVects observed
with E749-57 TriVax was evaluated against larger and
more established TC-1 tumors. The results shown in
Fig. 3a demonstrate that therapeutic immunization with
TriVax 11 days post-tumor inoculation resulted in 100 %
complete rejections and increased survival. The therapeu-
tic eVectiveness of E749-57 TriVax was also examined
using a diVerent tumor cell line called C3.43, which also
expresses the HPV16-E7 antigen. As presented in Fig. 3b,
TriVax using the E749-57 peptide resulted in complete
rejection of 6-day established C3.43 tumors. Furthermore,
at the conclusion of this experiment (day 30), consider-
able numbers of E749-57-speciWc CD8 T cells remained
Fig. 2 Therapeutic eVects induced by TriVax and BiVax immuniza-
tion against established TC-1 tumors. a Mice (n = 3 per group) were
inoculated (s.c.) with 3 £ 105 TC-1 cells and vaccinated (i.v.) 6 days
later with E749-57 peptide alone, BiVax, peptide plus !CD40 mAb, or
TriVax. Identical booster immunizations were given on day 13. Tumor
growth was measured (two opposing diameters) and recorded twice at
week. None of mice from the E749-57 and E749-57 + !CD40 mAb groups
rejected their tumors. One mouse from the BiVax group and all 3 mice
from the TriVax group rejected their tumors. b The percentage of anti-
gen-speciWc (tetramer positive) CD8 T cells in blood of the mice from
the experiment shown on a measured at diVerent time points. Only 2
measurements were done in the mice immunized with peptide alone
because these mice did not survive beyond day 24. c Mice (n = 4 per
group) were inoculated (s.c.) with 3 £ 105 TC-1 cells and vaccinated
(i.v.) 6 days later with TriVax prepared with either E749-57 or Ova176-
183 as indicated. Identical booster immunizations were given on day 13.
A non-vaccinated group (No Vax) was included as control. d The ther-
apeutic eVects of E749-57 BiVax were conWrmed using a larger number
of mice (6/group). In this experiment, half (3/6) of the mice in the Bi-
Vax-vaccinated group rejected their tumor, while all mice in the con-
trol group did not
 
Fig. 2 Therapeutic effects induced by TriVax and BiVax immunization against established TC-1 
tumors.  (a) Mice (n = 3 per group) were inoculated (s.c.) with 3x105 TC-1 cells and vaccinated 
(i.v.) 6 days later with E749-57 peptide alone, BiVax, eptide pl s αCD40 mAb or TriVax. Ide tical 
booster immunizations were given on day 13. Tumor growth as me su d (two opposing 
diameters) and recorded twice at week. None of mice from the E749-57 and E749-57 + αCD40 mAb 
groups rejected their tumors. One mouse from the BiVax group and all 3 mice from the TriVax 
group rejected their tumors.  (b) The percentage of antigen-specific (tetramer positive) CD8 T 
cells in blood of the ice from the experiment shown on panel “a” measured at different time 
points. Only 2 measurements were done in the mice immu ized with peptide alone because 
these mice did not survive beyond day 24.  (c) Mice (n = 4 per group) were inoculated (s.c.) with 
3x105 TC-1 cells and vaccinated (i.v.) 6 days later with TriVax prepared with either E749-57 or 
Ova176-183 as indicated. Identical booster immunizations were given on day 13. A Non-vaccinated 
group (No x) was include  as control. (d) The therapeutic ffects of E749-57 BiV x were 
confirmed using a larger number of mice (6/group).  In this experiment, half (3/6) of the mice in 
th  BiVax vacci ated group rejected th ir tumor, whil  all mice in the control group did not.  
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The impressive therapeutic anti-tumor effects observed with E749-57 TriVax 
was evaluated against larger and more established TC-1 tumors. The results 
shown in Fig. 3a demonstrate that therapeutic immunization with TriVax 11 days 
post-tumor inoculation resulted in 100 % complete rejections and increased 
survival. The therapeutic effectiveness of E749-57 TriVax was also examined using 
a different tumor cell line called C3.43, which also expresses the HPV16-E7 
antigen. As presented in Fig. 3b, TriVax using the E749-57 peptide resulted in 
complete rejection of 6-day established C3.43 tumors. Furthermore, at the 
conclusion of this experiment (day 30), considerable numbers of E749-57-specific 
CD8 T cells remained present on the spleens of the TriVax-immunized mice (Fig. 
3c). Moreover, the spleen CD8 T cells from the TriVax-immunized mice that 
rejected the C3.43 tumors were effective in recognizing C3.43 and TC-1 tumors, 
and such recognition was increased to some extent by IFNγ pretreatment of the 
tumor cells (Fig. 3d), which enhances the expression levels of MHC-I on both 
tumors (data not shown). 
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present on the spleens of the TriVax-immunized mice
(Fig. 3c). Moreover, the spleen CD8 T cells from the
TriVax-immunized mice that rejected the C3.43 tumors
were eVective in recognizing C3.43 and TC-1 tumors, and
such recognition was increased to some extent by inter-
feron-gamma (IFN!) pretreatment of the tumor cells
(Fig. 3d), which enhances the expression levels of MHC-I
on both tumors (data not shown).
Fig. 3 Therapeutic eVects induced by TriVax against HPV16-E7
expressing tumors. a Anti-tumor eVects against large TC-1 tumors.
Mice (6/group) were inoculated (s.c.) with 3 £ 105 TC-1 cells and
11 days later were immunized with TriVax, and a booster was given
13 days after prime. All of the mice immunized with TriVax rejected
their tumors. b Anti-tumor eVects against C3.43 tumors. Mice (6/
group) were inoculated with 3 £ 105 C3.43 cells (s.c.) and vaccinated
6 and 13 days later with TriVax. All TriVax-immunized mice rejected
their tumors. c Frequency of antigen-speciWc CD8 T cells in the
spleens of mice from the TriVax-immunized group shown in b was
determined 30 days after the prime. Numbers below each oval gate rep-
resent % tetramer-positive cells of the CD8 population. d CD8 T cells
were puriWed from pooled splenocytes of TriVax-vaccinated mice
shown in c, and tumor cell recognition was evaluated using IFN! ELi-
Spot assays. Stimulator cells were as follows: EL4 cells loaded or not
with E749-57 peptide, TC-1, and C3.43 tumor cells previously treated or
not with IFN! (100 U/ml, 24 h, to increase MHC-I expression). Results
represent the average number of spots from triplicate wells with SD
(error bars) of the means. e TriVax immunization confers long-term
protection against tumors. Mice (6/group) were inoculated (s.c.) with
3 £ 105 TC-1 cells and 6 and 13 days later received TriVax. By day 25,
all mice in the TriVax group rejected their tumors. On day 47, the mice
were re-challenged with 3 £ 105 TC-1 on their right Xanks and 3 £ 105
C3.43 on their left Xanks. None of the tumors grew. As controls
(CTRLs), 3 naïve mice were inoculated with the same number of tumor
cells
 
Fig. 3 Therapeutic eff cts induced by TriVax against HPV16-E7 expressi g tumors. (a) A ti-
tumor effects against large TC-1 tumors. Mice (6/group) were inoculated (s.c.) with 3x105 TC-1 
cells and 11 days later were immunized with TriVax, and a booster was given 13 days after 
prime. All of the mice immunized with TriVax rejected their tumors. (b) Anti-tumor effects against 
C3.43 tumors. Mic  (6/group) were inoculat d with 3x105 C3.43 c ll (s.c.) and vacci ated 6 and 
13 days later with TriVax. All of the mice in the TriVax immunized mice rejected their tumors. (c) 
Frequency of antigen-specific CD8 T cells in the spleens of mice from the TriVax immunized 
group shown in panel “b” was determined 30 days after the prime. Numbers below each oval gate 
repr sent % t tramer positive cells of the CD8 populati . (d) CD8 T cells wer purified from 
pooled splenocytes of TriVax vaccinated mice shown in panel “c” and tumor cell recognition was 
evaluated using IFNγ ELiSpot assays. Stimulator cells were: EL4 cells loaded or not with E749-57 
peptide, TC-1 and C3.43 tumor cells previously treated or not with IFNγ (100 U/ml, 24 h, to 
increase MHC-I expression). Results represent the average number of spots from triplicate wells 
with SD (error bars) of the means.  (e) TriVax immunization confers long-term protection against 
tumors. Mice (6/group) were inoculated (s.c.) with 3x105 TC-1 cells and 6 and 13 days later 
received TriVax. By day 25 all mice in the TriVax group rejected their tumors. On day 47 the mice 
were re-challenged with 3x105 TC-1 on their right flanks and 3x105 C3.43 on their left flanks. None 
of the tumors grew. As controls (CTRLs), 3 naïve mice were inoculated with the same number of 
tumor cells. 
 45 
2.4.3 TriVax generates immunological memory that prevents tumor 
recurrences 
An effective therapeutic vaccination strategy should generate immune 
responses capable not only of eliminating tumor masses but also should be 
successful in preventing tumor recurrences by generating long-term immune 
memory. Thus, we evaluated whether E749-57 TriVax-treated mice that had 
successfully rejected TC-1 tumors would be able to respond to subsequent tumor 
re-challenges. The experiment shown in Fig. 3e shows that ≈ 1 month after 
rejecting their original TC-1 tumors, TriVax-immunized mice successfully resisted 
second tumor challenges using TC-1 and C3.43 cells, which were given 
separately to each mouse in opposite posterior flanks. Unvaccinated control mice 
developed both tumor challenges, which grew at an accelerated rate. 
 
2.4.4 Effect of route of administration in TriVax 
The results presented so far were obtained using immunizations that were 
administered intravenously (i.v.) since the goal was to generate a systemic 
immune response. However, since vaccines are generally not administered via 
the i.v. route, we examined whether TriVax would be effective against 6-day 
established TC-1 tumors if it were administered intramuscularly (i.m.). As shown 
in Fig. 4a, i.m. E749-57 TriVax induced tumor clearance of 100 % of treated mice, 
while tumors in the non-vaccinated mice grew at a fast rate. Notably, the 
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frequency of antigen-specific (tetramer positive) CD8 T cells in blood of these 
mice, measured 11 days after the booster immunization, was rather low (range 
2.3-10.5 %, Fig. 4b), compared to the values we routinely observed in mice 
immunized i.v. (>50 %). In addition, one of the six i.m. vaccinated mice in this 
experiment (the one with the lowest numbers of antigen-specific CD8 T cells) 
developed a tumor recurrence at the original injection site on day 82 (post prime), 
suggesting that the tumor had not been totally eradicated. 
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TriVax generates immunological memory that prevents 
tumor recurrences
An eVective therapeutic vaccination strategy should gener-
ate immune responses capable not only of eliminating
tumor masses but also should be successful in preventing
tumor recurrences by generating long-term immune mem-
ory. Thus, we evaluated whether E749-57 TriVax-treated
mice that had successfully rejected TC-1 tumors would be
able to respond to subsequent tumor re-challenges. The
experiment shown in Fig. 3e shows that »1 month after
rejecting their original TC-1 tumors, TriVax-immunized
mice successfully resisted second tumor challenges using
TC-1 and C3.43 cells, which were given separately to each
mouse in opposite posterior Xanks. Unvaccinated control
mice developed both tumor challenges, which grew at an
accelerated rate.
EVect of route of administration in TriVax
The results presented so far were obtained using immuniza-
tions that were administered intravenously (i.v.) since the
goal was to generate a systemic immune response. How-
ever, since vaccines are generally not administered via the
i.v. route, we examined whether TriVax would be eVective
against 6-day established TC-1 tumors if it were adminis-
tered intramuscularly (i.m.). As shown in Fig. 4a, i.m. E749-
57 TriVax induced tumor clearance of 100 % of treated
mice, while tumors in the non-vaccinated mice grew at a
fast rate. Notably, the frequency of antigen-speciWc (tetra-
mer positive) CD8 T cells in blood of these mice, measured
11 days after the booster immunization, was rather low
(range 2.3–10.5 %, Fig. 4b), compared to the values we
routinely observed in mice immunized i.v. (>50 %). In
addition, one of the six i.m. vaccinated mice in this experi-
ment (the one with the lowest numbers of antigen-speciWc
CD8 T cells) developed a tumor recurrence at the original
injection site on day 82 (post prime), suggesting that the
tumor had not been totally eradicated.
Mechanism of anti-tumor eVects of TriVax
Lastly, to assess the roles of various lymphocyte subsets
and the requirements of eVector cytokines, the anti-tumor
eYcacy of E749-57 TriVax was examined in CD8-, CD4-,
and NK-depleted mice and in IFN!KO and IFN"#R KO
mice. The results in Fig. 5a show, as expected, that mice
depleted of CD8 T cells were unable to control tumor
growth and closely resembled the non-vaccinated mice. On
the other hand, 100 % of the CD4- and NK cell-depleted
mice rejected their tumors. Surprisingly, the TriVax-immu-
nized IFN! KO and IFN"#R KO mice were able to control
tumor growth to a great degree, and in some instances,
complete rejections were observed (Fig. 5b). When the
intensity of the CD8 T-cell responses in immunized IFN!
!" and IFN"#R KO tumor-free mice was evaluated after
TriVax immunization (prime/boost), it became evident that
absence of IFN! had little eVect, while the role of type-I
IFN in generating high CD8 T-cell numbers was clearly
more important (Fig. 5c).
Discussion
The goal of the present studies was to assess the eVective-
ness of a new and potent peptide vaccination strategy for its
therapeutic eVectiveness against tumors expressing the
HPV16-E7 oncogene product. This viral product is an ideal
TAA for developing T cell–based immunotherapy against
Fig. 4 Anti-tumor eYcacy of intramuscularly administered TriVax.
a Mice were inoculated s.c. with 3 £ 105 TC-1 cells. Six days later
were vaccinated i.m. with TriVax (TriVax IM) and an identical booster
was given on day 13. Tumor growth was measured as described previ-
ously. By day 25, all mice (6/6) vaccinated with TriVax rejected tumor,
but by day 66, one of the mice developed a tumor mass at the original
site (not shown). All of the (3/3) non-vaccinated mice developed large
tumors and did not survive. b Frequency of antigen-speciWc CD8 T
cells (tetramer positive) in the blood of the mice shown in a measured
11 days after boost. Numbers below the oval gates represent the % tet-
ramer-positive cells of the CD8 T-cell population
 
Fig. 4 Antitumor efficacy of i ra uscul rly administe ed TriVax. (a) Mice were inoculated s.c. 
with 3x105 TC-1 cells. Six days later were vaccinated i.m. with TriVax (TriVax IM) and an identical 
booster was given on day 13. Tumor growth was measured as described previously. By day 25, 
all mice (6/6) vaccinated with TriV x rej cted tumor, but by day 66, one of the mice developed a 
tumor mass at the original site (not shown). All of the mice (3/3) n n-v ccinated mice developed 
large tumors and did not survive. (b) Frequency of antigen-specific CD8 T cells (tetramer positive) 
in the blood of the mice shown in panel “a” measured 11 days after boost. Numbers below the 
oval gates represent the % tet amer positive cells f the CD8 T cell population.  
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2.4.5 One TriVax injection is sufficient to elicit effective, long-lasting anti 
tumor effect 
Next we wanted to determine if administration of booster shots are 
necessary for TriVax immunogenicity and antitumor effect. To do so mice 
(5/group) were inoculated with 3x105 TC-1 cells s.c., 6 days later vaccinated with 
TriVax i.v., and a booster was given on days 7, 13 or not at all and the 
percentages of tetramer positive cells measured in blood. As shown in Fig. 5, 
even though a single injection generated low numbers of antigen specific CD8 T 
cells (Fig. 5a) these mice were able to control tumor growth and ultimately 
completely reject tumor at the same level that mice that received a booster shot 
(Fig. 5b). To ensure that mice were completely cured from tumor, mice were 
depleted of CD8 cells by administration of 500 µg of αCD8 antibodies i.p. on 
days 43, 46, 49, 62 and 65 after prime, and continue to be followed for the 
presence of palpable tumors. Mice remained tumor free until the end of the 
experiment 90 days after prime. It is possible that the low number of antigen 
specific CD8 T cells detected in peripheral blood is due to the presence of the 
majority of these cell are in other tissues, it is also possible that the tumor itself 
as a booster for the antigen specific cells generated after prime leading to tumor 
clearance. 
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Fig. 5 One TriVax injection is sufficient to elicit effective, long-lasting anti tumor effect. (a) Mice 
(5/group) were inoculated with 3x105 TC-1 cells s.c., 6 days later mice were vaccinated with 
TriVax i.v., a booster was given on days 7, 13 or not at all and the percentages of tetramer 
positive cells measured in blood on day 39. (b) Tumor growth was measured 2 times per week 
with automatic calipers. To ensure tumor was completely rejected, mice were depleted of CD8 
cells by administration of 500 µg of αCD8 antibodies IP on days 43, 46, 49, 62 and 65 after prime. 
A non-vaccinated group was included as control. 
 
 
2.4.6 Mechanism of anti-tumor effects of TriVax 
Lastly, to assess the roles of various lymphocyte subsets and the 
requirements of effector cytokines, the anti-tumor efficacy of E749-57 TriVax was 
examined in CD8-, CD4-, and NK-depleted mice and in IFNγ KO and IFNαβR KO 
mice. The results in Fig. 6a show, as expected, that mice depleted of CD8 T cells 
were unable to control tumor growth and closely resembled the non-vaccinated 
mice. On the other hand, 100 % of the CD4- and NK cell-depleted mice rejected 
their tumors. Surprisingly, the TriVax-immunized IFNγKO and IFNαβR KO mice 
were able to control tumor growth to a great degree, and in some instances 
complete rejections were observed (Fig. 6b). When the intensity of the CD8 T-
cell responses in immunized IFNγ and IFNαβR KO tumor-free mice was 
evaluated after TriVax immunization (prime/boost), it became evident that 
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absence of IFNγ had little effect, while the role of type-I IFN in generating high 
CD8 T-cell numbers was clearly more important (Fig. 6c). 
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HPV-transformed cells because it is recognized as a foreign
antigen. Thus, the lack of immunological tolerance allows
the generation of high-avidity T-cell responses, which con-
trasts with lower-avidity T cells generated against other
types of TAAs that are expressed by normal tissues (e.g.,
melanosomal products, p53, HER2/neu). We have reported
that TriVax using epitopes from melanosomal TAA such as
Trp1 and Trp2 that are expressed on normal cells, although
generate large numbers of antigen-speciWc T cells that
diminish tumor growth, are incapable of rejecting estab-
lished B16 melanomas in WT mice [23, 27].
Because the HPV16-E7 protein plays a critical role in
maintaining the transformed phenotype of the tumor cells
[28, 29], the possible appearance of antigen-loss mutants,
which is often seen in immunotherapy [10], should be
diminished. The results presented here using two HPV16
mouse tumor models (TC-1 and C3.43) demonstrate that
immunization with a synthetic peptide representing an
exact CD8 T-cell epitope in combination with poly-IC and
!CD40 mAb (TriVax) resulted in extensive antigen-spe-
ciWc T-cell responses that were durable and capable of
eradicating established tumors. Others have reported that
vaccines prepared with the minimal CD8 T-cell epitopes,
especially when administered systemically, are ineVective
because the peptides can be presented by non-professional
antigen-presenting cells (APCs) resulting in T-cell toler-
ance [30–32]. For this reason, some investigators advocate
the use of long synthetic peptides that require antigen pro-
cessing by professional APCs [20]. The present results and
previous work by our group [22, 23] demonstrate that vac-
cines containing minimal CD8 T-cell epitopes can be
highly immunogenic when provided together with poly-IC
and !CD40 mAb and in some cases with poly-IC alone
(Fig. 1). In fact, to the best of our knowledge, the magni-
tude of the responses we have observed with several mini-
mal CD8 T-cell epitopes using TriVax (HPV16-E749-57,
Trp1455-463/9M, Trp2180-188, Ova257-264, rNEU66-74) is far
superior to what has been reported using other peptide vac-
cines (with either short or long synthetic peptides), when
administered with conventional adjuvants (e.g., IFA),
pulsed onto DCs or when using recombinant DNA vac-
cines. Although the magnitude of the T-cell responses
achieved with TriVax in mice is impressive, we do not
know whether similar eVects can be accomplished in
humans following the same strategy. Moreover, it will
be important to assess and closely monitor those potential
Fig. 5 Mechanism of therapeutic anti-tumor eVects of TriVax.
a Tumor growth in mice depleted of NK cells, CD4 T cells, and CD8
T cells vaccinated (i.v.) with TriVax. Mice (6/group) were inoculated
with 3 £ 105 TC-1 cells and 6 and 13 days later received TriVax. 1 and
3 days before the TriVax prime mice received depleting antibodies via
an i.p. injection as described in “Materials and methods”. b Tumor
growth in IFN" KO and IFN!#R KO mice vaccinated with TriVax in
the same manner as described in a. Non-vaccinated mice and TriVax-
vaccinated wild-type (WT) mice were used as controls in each experi-
ment. All of the TriVax WT, CD4-, and NK cell-depleted mice rejected
their tumors. One out of 6 mice in the IFN" KO group and 2/4 mice
from the IFN!#R KO group had complete tumor rejections. c Immune
responses elicited by TriVax in naïve IFN" KO and IFN!#R KO mice.
In a separate experiment, non-tumor-bearing wild-type (WT), IFN"
KO, and IFN!#R KO mice were vaccinated with TriVax (prime/boost,
13 days apart), and the percentage of tetramer-positive cells in blood
was determined 7 days after boost
!
 
Fig. 6 Mechanism of therapeutic anti-tumor effects of TriVax.  (a) Tumor growth in mic  depleted 
of NK cells, CD4 T cells and CD8 T cells vaccinated (i.v.) with TriVax. Mice (6/group) were 
inoculated with 3x105 TC-1 cells and 6 and 13 days later received TriVax. One and three days 
before the TriVax prime mice received depleting antibodies via an i.p. injection as described in  
“Materials and methods”. (b) Tumor growth in IFNγ KO and IFNαβR KO vaccinated with TriVax in 
the same manner as described in panel “ ”. Non-vaccinated mice and TriVax vaccinated wild 
type (WT) mice were used as co trols in each experim nt. All of the TriVax WT, CD4 and NK ll 
depleted mice rejected their tumors.  One out of 6 mice in the IFNγ KO group and 2/4 mice from 
the IFNαβR KO group had complete tumor rejections. (c) Immune responses elicited by TriVax in 
naïve IFNγ KO and IFNαβR KO mice. In a separate experiment, non-tumor bearing wild type 
(WT), IFNγ KO and IFNαβR KO mice were vaccinated with TriVax, (prime/boost, 13 days apart) 
and the percentage of tetramer positive cells in blood was determined 7 days after boost (3 mice 
per group). 
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2.5  Discussion  
The goal of the present studies was to assess the effectiveness of a new 
and potent peptide vaccination strategy for its therapeutic effectiveness against 
tumors expressing the HPV16-E7 oncogene product. This viral product is an 
ideal TAA for developing T cell-based immunotherapy against HPV-transformed 
cells because it is recognized as a foreign antigen. Thus, the lack of 
immunological tolerance allows the generation of high-avidity T-cell responses, 
which contrasts with lower-avidity T cells generated against other types of TAAs 
that are expressed by normal tissues (e.g., melanosomal products, p53, 
HER2/neu). We have reported that TriVax using epitopes from melanosomal 
TAA such as Trp1 and Trp2 that are expressed on normal cells, although 
generate large numbers of antigen-specific T cells that diminish tumor growth, 
are incapable of rejecting established B16 melanomas in WT mice [147, 245]. 
Because the HPV16-E7 protein plays a critical role in maintaining the 
transformed phenotype of the tumor cells, the possible appearance of antigen-
loss mutants, which is often seen in immunotherapy, should be diminished [233, 
246, 247]. The results presented here using two HPV16 mouse tumor models 
(TC-1 and C3.43) demonstrate that immunization with a synthetic peptide 
representing an exact CD8 T-cell epitope in combination with Poly-IC and αCD40 
mAb (TriVax) resulted in extensive antigen-specific T-cell responses that were 
durable and capable of eradicating established tumors. Furthermore, 
administration of a single shot of TriVax was sufficient to eradicate TC-1 s.c. 
 51 
tumor. Others have reported that vaccines prepared with the minimal CD8 T-cell 
epitopes, especially when administered systemically, are ineffective because the 
peptides can be presented by non-professional antigen-presenting cells (APCs) 
resulting in T-cell tolerance [248-250]. For this reason, some investigators 
advocate the use of long synthetic peptides that require antigen processing by 
professional APCs [239]. The present results and previous work by our group 
[147, 241] demonstrate that vaccines containing minimal CD8 T-cell epitopes can 
be highly immunogenic when provided together with Poly-IC and αCD40 mAb 
and in some cases with Poly-IC alone (Fig. 1). In fact, to the best of our 
knowledge, the magnitude of the responses we have observed with several 
minimal CD8 T-cell epitopes using TriVax (HPV16-E749-57, Trp1455/9M, Trp2180-188, 
Ova257-264, rNEU66-74) is far superior to what has been reported using other 
peptide vaccines (with either short or long synthetic peptides), when 
administered with conventional adjuvants (e.g., IFA), pulsed onto DCs or when 
using recombinant DNA vaccines. Although the magnitude of the T-cell 
responses achieved with TriVax in mice is impressive, we do not know whether 
similar effects can be accomplished in humans following the same strategy. 
Moreover, it will be important to assess and closely monitor those potential flu-
like toxic effects that could accompany the generation of large numbers of 
activated T cells. 
Although the combination of all three components of TriVax was clearly 
the most effective therapeutic strategy, possibly because it generated the 
strongest immune responses (Fig. 1a, b), immunization with peptide and poly- IC 
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(BiVax) or peptide plus αCD40 mAb was also quite effective in eliciting CD8 T-
cell responses that resulted in significant therapeutic benefit (Figs. 1, 2). These 
results indicate that the αCD40 mAb potentiates the effectiveness of TriVax, but 
is not essential and that Poly-IC plays the major role of adjuvant in this 
vaccination strategy. It is possible that with additional immunization boosters, the 
efficacy of BiVax could improve to the level of TriVax to attain 100 % tumor 
rejections by increasing T-cell numbers. On the other hand, we cannot rule out 
that the αCD40 mAb may facilitate the generation of CD8 T cells with increased 
function and that simply inducing high numbers of T cells will be insufficient to 
achieve maximal therapeutic responses. Notwithstanding, our results indicate 
that even low numbers of antigen-specific CD8 T cells, which were induced by 
peptide plus αCD40 mAb, TriVax administered i.m. and TriVax prime only were 
sufficient to effectively control the rate of tumor growth. However, complete and 
durable rejections in all mice were only achieved when high numbers of antigen-
specific CD8 T cells were produced or TriVax was administered i.v.  
The rationale for the use of αCD40 mAb in the generation of CD8 T-cell 
responses is to provide the strong costimulatory signal to antigen-presenting 
dendritic cells (DCs), which is usually supplied by CD40 ligand (CD40L) 
expressing CD4 T helper cells. The CD40/CD40L costimulatory interaction has 
been proposed to be critical for the generation of memory CD8 T cells capable of 
persisting for long time periods [251]. Nevertheless, BiVax showed to be effective 
in generating high numbers of long-lasting CD8 T-cell responses, presumably in 
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the absence of CD40 ligation. Furthermore, depletion of CD4 T cells does not 
decrease (but slightly increases) the generation of antigen- specific CD8 T cells 
by BiVax (data not presented), ruling out that this vaccine somehow also 
stimulates CD4 T cells. The ability of BiVax to trigger strong T-cell responses to 
the E749-57 peptide appears to be somewhat unique, since other potent CD8 T-
cell epitopes such as Ova257-264 (SIINFEKL) and melanoma Trp1455-463/9M (T 
APDNLGYM) are ineffective and require αCD40 mAb in addition to Poly-IC (E. 
Celis, unpublished). Specific characteristics such as solubility that could influence 
the formation of micro-aggregates and serum protease resistance affecting the 
peptide’s pharmacokinetics are likely to determine in great part whether a peptide 
is able to trigger T cell responses when administered in the BiVax format. Poly-IC 
is a double-stranded synthetic RNA that stimulates TLR3 and cytoplasmic RNA 
helicases (RIG-I and MDA5) resulting in the activation of DCs and the generation 
of high amounts of type-I IFN [252, 253], which is considered important for the 
induction of effective T-cell responses [254]. Our results indicate that in the 
absence of type-I IFN signaling (in IFNαβR KO mice), TriVax was less effective 
in generating sufficient numbers of CD8 T cells that could be necessary for total 
disease eradication (Fig. 6b, c). Nevertheless, it was interesting to note a 
substantial anti-tumor effect of TriVax in the absence of type-I IFN signals, which 
could be due to the participation of other T-cell stimulatory cytokines such as 
IL12 generated by the combination of Poly-IC and αCD40 mAb. It was somewhat 
unexpected to observe a significant anti-tumor effect of TriVax in the absence of 
IFNγ (Fig. 6b), since this cytokine is considered to be critical for the anti-tumor 
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effects of CD8 T cells [255-257]. Nevertheless, our results indicate that IFNγ may 
play some role in the overall effectiveness of TriVax to completely reject the 
tumors. These results contrast with our recent findings in the B16 melanoma 
system in which IFNγ was shown to play a negative role in the anti-tumor effects 
of TriVax using Trp1455-463/9M and Trp2280-288, where complete rejections of 
established tumors were observed in IFNγ KO mice and not in WT mice [245]. 
Thus, it is possible that IFNγ plays an effector role with the TC-1 tumors, limiting 
cell proliferation or that the increase MHC-I expression induced by IFNγ in these 
cells enhances T cell recognition. 
In summary, the results presented herein in a mouse model of HPV-
induced cancer demonstrate the feasibility of a novel and potent peptide 
vaccination strategy that could be adopted for CC or other HPV-induced 
malignancies. Both Poly-IC and αCD40 mAb for human clinical use are in 
development and together with known human CD8 T-cell epitopes could be 
administered using the TriVax format with the goal of reducing tumor growth and, 
perhaps as shown here in mice, eradicate established disease. 
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Chapter 3: BiVax: A Peptide/Poly-IC Subunit Vaccine That Mimics an Acute 
Infection Elicits Vast and Effective Anti-Tumor CD8 T Cell Responses 
 
3.1  Abstract 
Therapeutic vaccines for the treatment of cancer are an attractive 
alternative to some of the conventional therapies that are currently used. More 
importantly, vaccines could be very useful to prevent recurrences when applied 
after primary therapy. Unfortunately, most therapeutic vaccines for cancer have 
performed poorly due to the low level of immune responses that they induce.  
Previous work done in our laboratory in cancer mouse models demonstrated that 
vaccines consisting of synthetic peptides representing minimal CD8 T cell 
epitopes administered i.v. mixed with Poly-IC and αCD40 antibodies (TriVax) 
were capable of inducing massive T cell responses similar to those found during 
acute infections. We now report that some peptides are capable of inducing large 
T cell responses after vaccination with Poly-IC alone (BiVax). The results show 
that the differences between TriVax and BiVax immunogenicity and antitumor 
effect is most likely due to the numbers of antigen specific CD8 T cells generated 
after vaccination. Amphiphilic peptides are more likely to function as strong 
immunogens in BiVax and that systemic immunizations (i.v. or i.m.) were more 
effective than local (s.c.) vaccine administration. The immune responses induced 
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by BiVax were found to be effective against established tumors in two mouse 
cancer models. The role of various immune related pathways such as type-I IFN, 
CD40 costimulation, CD4 T cells TLRs and MDA5 was examined. The present 
findings could facilitate the development of simple and effective subunit vaccines 
for diseases where CD8 T cells may hold a therapeutic benefit. 
 
3.2  Introduction 
CD8 T cells play an important role in the control of intracellular infectious 
agents and have the potential to mitigate malignant diseases. The CD8 TCR 
recognizes small peptides bound to MHC class I (MHC-I) products on APCs. 
These peptides known as CD8 T cell epitopes are usually derived from 
processed proteins corresponding to microbial components or TAAs. The 
identification of these peptides has lead to developing epitope-based vaccines to 
induce antigen-specific CD8 T cell responses for the prevention or treatment of 
various infections and malignancies [258]. Synthetic peptides containing defined 
CD8 T cell epitopes constitute an attractive approach for vaccine development 
due to their ease of manufacturing and safety as compared to other vaccine 
types such as recombinant DNA-derived proteins, plasmids, viruses or 
genetically engineered cells [259]. However, most peptide vaccines generate 
minute CD8 T cell responses as compared to the T cell levels observed during 
acute infections. Without a doubt the vaccine’s poor immunogenicity results in 
suboptimal clinical benefit against an established/advanced disease and have 
enticed many clinical researchers to seek other immunotherapy alternatives 
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[260]. These disappointing results could be explained in part by the use of weak 
immunological adjuvants (e.g., IFA), suboptimal peptide formulations and 
inappropriate routes of vaccine administration. 
For some time our laboratory has been involved in the optimization of 
peptide vaccines for the induction of anti-tumor CD8 T cell responses [261, 262]. 
We have recently proposed that in order to have an impact against established 
tumors, the vaccines must elicit a CD8 T cell response resembling the magnitude 
and duration of the responses observed during acute viral infections, where more 
than one third of the circulating CD8 T cells show specificity for the offending 
microorganism [263]. We have reported that synthetic peptides corresponding to 
the minimal CD8 T cell epitope administered intravenously mixed with Poly-IC 
and costimulatory αCD40 antibodies resulted in the induction of vast numbers of 
antigen-specific CD8 T cells in mice, resembling the levels observed during acute 
infections [241]. Furthermore, experiments performed in several mouse cancer 
models demonstrated that this vaccination strategy (TriVax) was highly effective 
against established tumors resulting in many instances in complete disease 
eradication [147, 227]. Although these results were highly encouraging for 
developing therapeutic peptide vaccines for humans, there are serious concerns 
regarding the systemic use of agonistic αCD40 antibodies due to potential 
deleterious effects such as cytokine storm and or liver toxicity [264, 265]. 
We report here a novel strategy (BiVax) that allows synthetic peptides to 
induce high levels of antigen-specific CD8 T cells, when administered in 
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combination with Poly-IC without the use of costimulatory αCD40 antibodies. 
Immune responses produced by BiVax were highly dependent on the 
simultaneous administration of peptide and Poly-IC, on the peptide composition, 
vaccine formulation and route of administration. As expected, the magnitude of 
the response was dependent on the expression of the Poly-IC receptors TLR3 
and MDA5. Peptide combinations with supposedly potent agonists to other TLRs 
(CpG, Pam3CSK4) were not able to generate the strong CD8 T cell responses. 
Interestingly, the magnitude and duration of the CD8 T cell responses generated 
by peptide and Poly-IC mixtures did not rely on the presence of CD4 T cells, 
scavenger receptor-A (SR-A) or type-I IFN signals and was minimally affected by 
the absence of CD40 signaling.  The present findings may help to clarify some of 
the mechanisms involved in the generation of massive and lasting CD8 T cell 
responses by peptide epitope vaccines and could facilitate the development of 
more effective immunotherapies for cancer. 
 
3.3  Materials and Methods 
3.3.1 Mice and cell lines 
Six- to eight-week-old female C57BL/6 (B6) mice were obtained from the 
National Cancer Institute/Charles River Program (Wilmington, MA). CD40-
deficient (B6.129P2-Tnfrsf5tm1Kik/J), TLR3-deficient (B6;129S1-Tlr3tm1Flv/J) mice in 
a B6 genetic background were purchased from The Jackson Laboratory (Bar 
Harbor, ME). Breeder mice deficient on MDA5 (Ifih1) and interferon alpha/beta 
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receptor (IFNαβR,) both on a B6 background were kindly provided by Dr. Marco 
Colonna (Washington University School, of Medicine, St. Louis MO) and Philippa 
Marrack (National Jewish Medical and Research Center, Denver CO), 
respectively. Mice deficient for the expression of both scavenger receptors-A 
(SR-A) and MARCO (double knockouts on a B6 background) were a gift from 
Drs. Jim Mulé and Shari Pilon-Thomas (Moffitt Cancer Center). EL4 thymoma 
cells were purchased from the American Type Culture Collection (Manassas, 
VA). The TC-1 tumor cell line, expressing HPV16-E7 antigen was obtained from 
Dr. T-C Wu (Johns Hopkins University, Baltimore, MD). The B16-F10 mouse 
melanoma cell line was provided by Dr. Alan Houghton (Memorial Sloan 
Kettering Cancer Center, New York, NY). 
 
3.3.2 Reagents 
All synthetic peptides were purchased from A&A Labs (San Diego, CA). 
Lipopeptides were synthesized by attachment of 2 palmitic acid (Pam) chains via 
the 2 amino groups of an N-terminal lysine. The purity and identity of peptides 
were determined by high-performance liquid chromatography and mass 
spectrometry analysis by the vendor. Amino acid sequences of the peptides used 
in these study are shown throughout the text and in the corresponding figures. All 
peptides were solubilized at 20 mg/ml in DMSO-TFA (99.9%/0.1%) and stored in 
aliquots at -80 °C. 
Polyinosinic:polycytidylic acid (Poly-IC) stabilized with poly-lysine and 
carboxy-methylcellulose (Poly-ICLC/Hiltonol) was kindly provided by Dr. Andres 
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Salazar (Oncovir, Inc., Washington, DC).  Synthetic oligodeoxynucleotides 
containing CpG motifs, CpG-1826 (Class-B; 5’-tccatgacgttcctgacgtt-3’) and CpG-
1585 (Class-A; 5’-ggGGTCAACGTTGAgggggg-3’) were prepared at the Mayo 
Clinic Molecular Biology Core and were kindly provided by Dr. R. Vile (Mayo 
Clinic, Rochester, MN). Poly-AU and Pam3CSK4 were purchased from 
InvivoGen (San Diego, CA). Antibodies for in vivo use in mice, anti-PD-L1 (clone 
10F.9G2) and anti-CD4 (clone GK1.5) and anti-CD8 (clone 2.43) were purchased 
from BioXCell (West Lebanon, NH). 
Fluorochrome-labeled antibodies were obtained from eBioscience, Inc 
(San Diego, CA). Fluorescence-labeled MHC-I/peptide tetramers were kindly 
provided by the National Institute of Allergy and Infectious Disease Tetramer 
Facility at the Emory University (Atlanta, GA NIH). 
 
3.3.3. Immunizations and assessment of immune responses 
Vaccines were freshly prepared by diluting and mixing the peptides and 
TLR agonists in PBS to the appropriate concentration in order to inject 30-200 µg 
peptide (depending on the peptide) and 50-100 µg TLR agonist in 50-200 µl per 
mouse (depending in the route of administration). In most instances vaccines 
were administered intravenously (200 µl/injection in the tail vein). In some 
experiments mice were vaccinated subcutaneously or intramuscularly (50 
µl/injection in 2 sites per mouse). Mice received 1-3 booster immunizations every 
5-7 days. In some experiments, mice were depleted of CD4 T cells using αCD4 
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monoclonal antibodies administered i.p. 300 µg twice, on days -2 and 0 before 
each immunization.  Immune responses were mostly assessed by tetramer 
staining using peripheral blood samples obtained at various time points or in 
spleen cells at the termination of the experiments. Fluorescence was measured 
using either a FACSCalibur or an LSRII flow cytometer (BD Biosciences, San 
Jose, CA) and analyzed using FlowJo software (Ashland, OR).  Immune 
responses were also determined in spleens with EliSpot assays as described 
[147]. 
 
3.3.4 Evaluation of vaccine therapeutic anti-tumor effect 
Mice received 3x105/mouse tumor cells (TC-1 or B16-F10) s.c. in a 
shaved rear flank 5-6 days (as noted) before their primary immunization. In some 
instances, mice received 200 µg anti-PD-L1 antibodies i.p. on days 1 and 3 post-
immunization. Tumor growth was monitored every 2-4 days in individual tagged 
mice by measuring 2 opposing diameters with a set of calipers. Mice were 
euthanized when the tumors area reached 400 mm2. Results are presented as 
the mean tumor size (area in mm2) ± SD for every treatment group at various 
time points until the termination of the experiment.  
 
3.3.5 Peptide curves 
As a mean to gauge the avidity of CD8 T cells from TriVax and BiVax 
vaccinated mice for their cognate peptide, CD8 T cells from spleens of 
vaccinated mice were co-cultured in triplicated for 36-48 hours with irradiated 
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EL4 cells that were pulsed for 3 hours with decreasing amounts of the E749-57 
peptide. Then the supernatants were collected and the amount of IFNγ produced 
assessed by means of ELISA. Briefly, ELISA plates were coated with αIFNγ 
capture antibody at 4°C overnight, blocked with blocking solution for 2.5 hours at 
room temperature and the 100 µl of supernatant added to the plate and 
incubated for 24 hours at 37°C. Then plates were washed and incubated at room 
temperature with biotinilated αIFNγ for 2.5 hours and for 1 hour with horseradish 
peroxidase (HRP)-Avidin. The plates were revealed with the addition of 3,3’,5,5’-
Tetramethylbenzidine (TMB) substrate and read within 20 minutes at 420nm in 
an automatic ELISA plate reader. Results are expressed as total amount of IFNγ 
produced and as percentage of maximum response. 
 
3.3.6 Statistical analyses 
Unpaired Student’s t test was used to determine statistical significance of 
differences in numbers of antigen specific CD8 T cells (EliSpot, tetramer) and 
cytokine levels (ELISA). Tumor sizes between 2 populations throughout time 
were analyzed for significance using 2-way ANOVA tests. All analysis and 
graphics were done using GraphPad Prism 5.01 (GraphPad Software, San 
Diego, CA). 
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3.4 Results 
3.4.1 TriVax and BiVax differential effects are due to the quantity of 
antigen specific CD8 T cells generated after vaccination 
We recently reported that 2 sequential peptide immunizations (prime and 
boost, 2 weeks apart) using the CD8 T cell epitope HPV16-E749-57 (RANYNIVTF) 
combined with Poly-IC and αCD40 monoclonal antibodies (TriVax) resulted in 
huge CD8 T cell responses capable of eradicating established TC1 tumors in 
100% the mice (Chapter 2, published in Cancer Immunology Immunotherapy 
[227]). Interestingly, vaccination with a mixture of HPV16-E749-57 and Poly-IC, 
without the αCD40 mAb (BiVax) was able to induce a CD8 T cell response, but 
the magnitude was substantially lower (~30%) as compared to TriVax and only 
30-50% of the vaccinated mice were able to completely reject their tumors.  
We wanted to examine the source of these differential effects. To do so 
we vaccinated mice with either TriVax or BiVax i.v. and checked the number of 
antigen specific cells generated in blood and spleen after the booster shot given 
13 or 6 days after prime, respectively (Fig. 7a).  As shown before BiVax 
generated approximately half of the numbers of tetramer positive cells both in 
blood and spleens. Next we wanted to know if these levels of antigen specific 
cells co-related with the ability of the CD8 T cells to recognized tumor cells in 
vitro. Indeed CD8 T cells from BiVax vaccinated mice were less efficient in 
recognizing tumor cells in an EliSpot assay (Fig. 7b). These results might be due 
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to the fact that (i) CD8 T cells generated by TriVax have a higher avidity for the 
tumor cells or (ii) the sheer number of CD8 T cells are responsible for these 
differential effect antigen and/or (iii) somehow CD8 T cells from TriVax 
vaccinated mice persist for a longer period of time than those generated by 
BiVax immunization. To explore these options CD8 T cells from spleen of 
vaccinated mice (from mice on figure 7a) were positive selected and co-culture 
with irradiated EL4 cells pulsed with decreasing amount of the E749-57 peptide 
then the amount of IFNγ produced was measured using ELISA. As shown on 
figure 7c and d, even though CD8 T cells from TriVax vaccinated mice produced 
double the amount of IFNγ at any given dilution of stimulating peptide, the curve 
of percentage of maximum response are almost identical, indicating that CD8 T 
cells from both TriVax and BiVax vaccinated mice have the same avidity for the 
E749-57 peptide. Lastly, we followed the persistency of antigen specific CD8 T 
cells in the blood of mice vaccinated with BiVax of TriVax, to do so mice were 
immunized with TriVax or BiVax using either the E749-57 peptide (Fig. 7e) or the 
Pam Trp1 peptide (Fig. 7f); a booster shot was given 9 days later and the 
percentage of tetramer positive CD8 T cells determined at different time points 
for two months. We found that antigen specific CD8 T cells from BiVax-HPV and 
TriVax-HPV vaccinated mice follow the same kinetics and the same hold true for 
another tumor model antigen (Pam Trp1). 
 65 
 
Fig 7. TriVax and BiVax differential effects are due to the quantity of antigen specific CD8 T cells 
generated after vaccination. (a) Mice (3 per group) were vaccinated with TriVax or BiVax i.v. a 
booster shot was given 13 and 6 days after the prime (respectively) and the percentage of 
tetramer positive CD8 T cells determine in blood and spleens 7 days after boost. (b) CD8 T cells 
from spleen of vaccinated mice (from mice on figure a) were positive selected and a fraction of 
them co-cultured with target cells in an EliSpot assay as described in “Materials and Methods”; 
the other fraction was used to measure IFNγ production after co-culture the CD8 T with irradiated 
EL4 cells pulsed with decreasing amount of the E749-57 peptide using ELISA, results are 
expressed as total amount of IFNγ produced (c) and as percentage of maximum response (d). 
Mice (3 per group) were immunized with TriVax or BiVax using either the E749-57 peptide (e) or the 
Pam Trp1 (f) peptide; a booster shot was given 9 days later and the percentage of tetramer 
positive CD8 T cells determined at different time points for two months. 
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3.4.2 Additional BiVax boosters improve vaccine immunogenicity and 
correlates with enhance anti tumor effect 
To optimize BiVax in the aforementioned tumor model we first assessed 
the possibility of reducing the time interval between prime and booster 
immunizations and adding another booster to increase the speed and intensity of 
immune response and enhance the anti-tumor effect. As shown in Fig. 7a, a time 
interval between prime and boost of 7 or 5 days resulted in ~40% tetramer 
positive CD8 T cells, which is identical to the levels previously observed when 
prime and boost were administered 13-21 days apart [227]. On the other hand, a 
substantially lower response was observed when the booster immunization was 
given 3 days after the prime. Next, we assessed whether an additional booster 
immunization (prime and 2 boosts, 6-7 days apart), would further augment the 
numbers of antigen-specific CD8 T cells and would improve the outcome in TC-1 
tumor-bearing mice. Indeed the additional BiVax booster immunization increased 
the levels of circulating tetramer positive CD8 T cells to ~60% in both tumor-free 
and tumor bearing mice (Fig. 8b). Most importantly, all the mice that received the 
prime+2 booster BiVax therapy rejected their tumors (Fig. 8c).  
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Fig. 8 Additional BiVax boosters improve vaccine immunogenicity and correlates with enhanced 
anti tumor effect. (a) B6 mice were given a boost 3, 5 and 7 days after prime; five days later the 
percentage of tetramer positive CD8 T cells was determined in blood (n= 3 mice per group). (b) 
Mice were inoculated with 3x105 TC-1 cells s.c.; six days later they were primed with BiVax E749-
57 and boosted 6 and 14 days later. The percentage of tetramer positive CD8 T cells was 
determined in blood 7 or 8 days after boost. A tumor bearing non vaccinated group and a tumor 
free vaccinated group were included as controls. *No statistical significant differences between 1 
and 2 boosts in tumor free mice were observed. **Statistical significance between 1 and 2 boosts 
(P<.001) in tumor bearing mice was observed.  (c) Tumor sizes were assessed 2-3 times a week 
using automatic calipers. Mice were euthanized when tumors reached 2cm in diameter on either 
side. After tumor rejection mice were CD8 T cell depleted by i.p. inoculation with 500 µg of αCD8 
antibody (days 43, 46, 49, 62 and 65 after prime) and no tumors appeared. CD8 T cell depletion 
was monitored by flow cytometry (n= 6 mice treatment group, 3 mice in the control groups). 
 
3.4.3 Effect of peptide residue substitution on BiVax immunogenicity 
Since variation on peptide residue that augment peptide binding to the 
MHC molecule can augment immunogenicity of peptides use in vaccination, we 
set out to test the effect of modifying the E749-57 peptide on BiVax 
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immunogenicity. To do so mice were vaccinated i.v. with the AAHYNIVTF (AF), 
AAHYNIVTL (AL), RAHYNIVTF (RF= E749-57) or RAHYNIVTL (RL) peptide; 
seven days later mice received a booster shoot and the percentages of tetramer 
positive CD8 T cells was measured at different time points. At the end of the 
experiment (day 27 after the prime) CD8 T cells from the aforementioned groups 
were positive selected from spleen and assayed for IFNγ production by means of 
EliSpot as described in “Materials and Methods”. As shown on Figure 9, even 
though binding prediction analysis indicates that mouse TCR should have higher 
binding affinity for the AL peptide followed by RL, AF and finally the RF peptide, 
our results show that the RF is actually the optimal peptide in our vaccine 
formulation. Not only the RF peptide generates the strongest immune response 
(Fig. 9a) but they also are more efficient in recognizing tumor cells in vitro (Fig. 
9b). 
 
Fig 9. Effect of peptide residue substitution on BiVax immunogenicity. (a) Mice (3 per group) were 
immunized with AAHYNIVTF (AF), AAHYNIVTL (AL), RAHYNIVTF (RF= E749-57) or RAHYNIVTL 
(RL) peptide i.v. seven days later mice received a booster shoot and the percentages of tetramer 
positive CD8 T cells was measured at different time points. (b) At the end of the experiment (day 
27 after the prime) CD8 T cells from the aforementioned groups were positive selected from 
spleen and assayed for IFNγ production by means of EliSpot as described in “Materials and 
Methods”.  
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3.4.4 Effect of peptide size on BiVax E749-57 immunogenicity. 
It has been suggested that vaccines using of long synthetic peptides 
containing within their sequence a defined CD8 T cell epitope will result in 
superior immune responses as compared to the use of peptides corresponding to 
the minimal epitope. The reasons proposed for the use of long peptides versus 
minimal peptides is that the former would need to be presented to the CD8 T 
cells by professional APCs such as DCs that are capable of internalizing and 
processing the long peptides, while the short minimal peptides could be 
presented by any MHC I expressing cell, potentially resulting in immune 
tolerance. In addition, some long peptides may contain MHC II binding 
sequences, which may stimulate CD4 T helper cells, further enhancing CD8 T 
cell activation end expansion. Thus, we assessed the immunogenicity using the 
BiVax approach of two long peptides of 13 and 35 residues, HPV16-E745-57 
(AEPDRAHYNIVTF) and HPV16-E743-77 
(GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR), containing within their 
sequences the minimal 9-residue HPV16-E749-57 CD8 T cell epitope (underlined). 
Both long peptides contain a CD4 T cell epitope, HPV16-E748-57 (DRAHYNIVTF) 
that could potentially increase the extent of the CD8 T cell responses. Contrary to 
what was predicted, the magnitude of the CD8 T cell responses observed in 
blood generated by the long peptides was considerably lower as compared to the 
result obtained using the minimal CD8 T cell epitope (Fig. 10a). The differences 
in immunogenicity between short and long peptides were even more evident 
when quantifying of the total numbers of antigen-specific CD8 T cells in spleens, 
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where the minimal epitope HPV16-E749-57 was found to generate vastly more 
antigen-specific CD8 T cells as compared to the long peptides (Fig. 10b). 
 
Fig. 10 Effect of peptide size on BiVax E749-57 immunogenicity. Mice were immunized with 
equimolar amounts of the E749-57, E745-57 and E743-77 peptides, a booster shot was given 7 days 
later and the percentage of tetramer positive CD8 T cells was determined in blood (a) and 
spleens (b) 14 and 22 days after prime, respectively. (c) Mice were primed (p) with either BiVax 
E749-57 or BiVax E744-77 (as indicated), 7 days later received a boost (b) with BiVax E749-57 and 7 
days after the boost the % tetramer positive cells were measured in blood. *No statistical 
significant difference was observed (n= 3 mice per group for all experiments). 
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strategy to other MHC-I binding peptides known to function as strong CD8 T cell 
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tumor-associated antigens for the mouse B16 melanoma. While Trp2180-188 
(SVYDFFVWL), is restricted by H-2Kb [266], the heteroclitic epitope Trp1455-463/9M 
(TAPDNLGYM) is restricted by H-2Db and has a substitution at position 9 (M for 
A) to improve MHC-I binding and immunogenicity [245, 267]. After a prime-boost 
BiVax with Trp2180-188, mice generated approximately 25% tetramer positive CD8 
T cells in blood (data not shown). In contrast, mice that received BiVax using 
Ova257-264 or Trp1455-463/9M produced a much lower T cell response (< 5%; data 
not shown). Comparing the sequences of the 2 epitopes that performed relatively 
well in BiVax (HPV16-E749-57 and Trp2180-188) with the 2 peptides that did not 
functioned well (Ova257-264 and Trp1455-463/9M) it became apparent that 
immunogenicity could not be clearly attributed to the overall 
hydrophobicity/hydrophilicity nature of the peptides, which could affect 
pharmacokinetics and antigen persistence after immunization. Ranking the 
peptides by the Kyte-Doolittle hydrophobicity scale [268] showed that the two 
most immunogenic peptides ranked 1st (Trp2180-188) and 3rd (HPV16-E749-57). 
However, when examining the hydrophobic and hydrophilic regions within each 
peptide it became evident that the 2 immunogenic peptides had an amphiphilic 
feature, where approximately one half of the molecule was highly hydrophobic 
while the other half was relatively hydrophilic. 
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3.4.6 Enhancing immunogenicity of Trp1-BiVax by increasing peptide 
amphiphilicity 
In view of the above, we examined whether the immunogenicity of Trp1455-
463/9M using BiVax, could be improved by increasing the peptide’s amphiphilic 
nature, which was achieved by the addition of 2 palmitic acid chains (Pam2) to 
the amino terminus end using a KMFV linker (the positive charges of K are 
eliminated with Pam conjugation). The results in Figure 11a demonstrate that 
peptide Pam2KMFVTAPDNLGYM was substantially more immunogenic than the 
minimal epitope TAPDNLGYM after a BiVax prime-boost protocol.  Interestingly, 
the minimal epitope was highly effective in boosting responses in mice that were 
generated by priming with Pam2KMFVTAPDNLGYM (Fig. 11b). The 
enhancement of immunogenicity was also achieved with the addition of 6-7 
hydrophobic residues to the amino terminus end of the peptide (Fig. 11c). On the 
other hand, adding only 3 hydrophobic residues did not affect the immunogenicity 
of the peptide. Extending the natural sequence of the epitope at the amino end 
by 7 residues (TNTEMFV) or adding the palmitic acid chains directly to the 
minimal T cell epitope (without the hydrophobic MFV linker) somewhat increased 
the immunogenicity as compared to the minimal epitope but to a much lower 
extent as compared to the peptide constructs that contained 6-7 hydrophobic 
residues or the Pam2KMFV extension. Lastly, extending the Trp1 peptide using 
charged or hydrophilic residues did not substantially improve the immunogenicity 
of the peptides using BiVax (data not shown).  The strategy to enhance the 
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peptide immunogenicity by generating an amphiphilic construct also worked well 
with Ova257-264 (data not shown). 
 
Fig. 11 Increasing peptide hydrophobicity enhances immunogenicity of BiVax. B6 mice were 
vaccinated i.v. on days 0 and 12 with BiVax composed of 150 µg of peptide and 50 µg of Poly-IC. 
(a) Mice (4 per group) received identical BiVax immunizations (prime/boost) with either minimal 
peptide (TAPDNLGYM) or palmitilated peptide (Pam2KMFVTAPDNLGYM). Immune responses 
were measured in blood 7 days after the boost.  **Statistical significance (P<.001) between the 2 
peptides was observed after the boost. (b) Mice (3 per group) were primed with palmitilated 
peptide and boosted with either the palmitilated peptide or the minimal peptide. On day 7 and 19, 
antigen-specific CD8 T cells were evaluated in blood by tetramer analysis.  *No statistical 
significant difference was observed between the 2 peptides after the boost. (c) Mice (3 per group) 
received two identical BiVax immunizations (prime-boost) with indicated peptides as described 
above. 7 days after the boost the antigen-specific CD8 T cells in blood were evaluated by 
tetramer analysis. Results represent the average percentage of tetramer positive CD8 T cells 
from 3 mice per group with SD (bars) of the means.(d) Purified spleen CD8 T cells from the 
experiment presented in panel (A) from the mice vaccinated with palmitilated peptide were 
evaluated for their ability to recognize tumor cells using an IFNγ secretion EliSpot assay. APCs 
used: Trp1455-463-pulsed EL4 (EL4 + pep), B16F10 melanoma, and Un-pulsed EL4 cells (negative 
control). Results represent the average number of spots from triplicate wells with SD (bars) of the 
means.  
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3.4.7 Therapeutic effects of BiVax-Trp1 against established melanomas 
A significant concern raised with the use of synthetic peptides as 
immunogens is that these vaccines will mainly generate low avidity T cells 
incapable of recognizing tumor cells that may express low density of 
peptide/MHC complexes on their surface. Nevertheless, as shown in Figure 11D, 
the CD8 T cells induced by BiVax with Pam2KMFVTAPDNLGYM (from hereafter 
simply referred to as “Pam2-Trp1”) were highly efficient in vitro in recognizing 
B16 melanoma cells. The therapeutic effect of BiVax immunization was 
evaluated against 5-day established subcutaneous B16-F10 melanoma tumors 
using Pam2-Trp1. Tumors grew at a significantly lower rate in mice that received 
2 sequential BiVax immunizations as compared to the untreated group (Fig. 12a). 
Moreover, the inclusion of 2 additional booster immunizations further increased 
the therapeutic effect of BiVax with Pam2-Trp1 (Fig. 12b) and the addition of PD1 
blockade (with αPD-L1 antibodies) to resulted in a remarkable therapeutic effect, 
where the majority of the mice (4/5) were able to completely reject their tumors 
(Fig. 12c). Interestingly, the control groups that received an irrelevant peptide 
(Pam2-Ctrl) and Poly-IC also showed a decrease in the rate of tumor growth but 
the therapeutic benefit was not as effective as compared to the use of the Pam2-
Trp1 peptide. The therapeutic effects of Pam2-Trp1 BiVax and the control Pam-
Ctrl BiVax disappeared when mice were depleted of CD8 T cells (data not 
presented). 
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Fig. 12 Therapeutic effects of BiVax against established B16 melanoma. B6 mice (4 per group) 
were inoculated s.c. on day 0 with 3×105 live B16-F10 cells and vaccinated i.v. with Pam-Trp1 or 
control Pam2-Ctrl BiVax. Tumor-bearing mice received 2 (a), or 4 (b) immunizations (arrows). (c) 
PD1 blockade was included in an experiment using 4 BiVax immunizations. Anti-PD-L1 mAb (200 
µg/dose) was administered i.p. on days 1 and 3 post-immunization, and two more antibody 
injections (on days 5 and 7) were added after the 4th BiVax immunization. Non-vaccinated mice 
(No Vax) and palmitilated irrelevant peptide-BiVax (Pam2-Ctrl) were included as controls. Tumor 
sizes were determined in individual mice by measuring 2 opposing diameters and are presented 
as tumor areas in square millimeters. Points, mean for each group of mice; gray bars, period of 
anti-PD-L1 mAb treatment; bars, SD. P values were calculated using 2-way ANOVA tests. *, 4 of 
5 mice in this group rejected their tumors. 
 
c 
a b 
 76 
3.4.8 Mechanisms involved in the immunogenicity of BiVax 
Next, we examined some of the mechanisms that could play a role in the 
generation of the strong CD8 T cell responses observed with BiVax.  First we 
assessed whether other TLR agonists also being considered as immune 
adjuvants performed with Pam2-Trp1. The results in Figure 13a demonstrate that 
only Poly-IC was capable of generating strong CD8 T cell responses with Pam2-
Trp1. The use of poly-AU (another TLR3 agonist) did not lead to the generation 
of the large CD8 T cell response observed with Poly-IC. Furthermore, CpG 
containing oligodeoxynucleotides of either type-A (CpG-1885) or type-B (CpG-
1826), which function as TLR9 agonists or the TLR2/TLR1 agonist Pam3CSK4 
failed to generate substantial T cell responses when administered mixed with 
Pam2-Trp1. Interestingly, combining CpG-1826 with Poly-IC reduced the 
magnitude of the CD8 T cell response as compared to the use of Poly-IC alone. 
On the other hand, the low T cell response generated by the administration of 
Pam2-Trp1 peptide with CpG-1826 could be dramatically increased with a BiVax 
booster containing Poly-IC (Fig. 13b). The results so far presented were obtained 
with Poly-IC formulation, known as poly-ICLC containing poly-lysine and carboxy-
methyl cellulose to stabilize the compound and protect it from RNAse 
degradation, which occurs mostly in primates [269]. Nevertheless, identical 
results were obtained using several commercially available non-stabilized Poly-
IC formulations (data not presented). 
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Fig. 13 Effect of various TLR agonists on BiVax immunization.  (a) Mice (3 per group) were 
immunized i.v. on days 0 and 12 with Pam2-Trp1 peptide and one of the following TLR agonists: 
50 µg Poly-IC, 100 µg CpG-1826, 100 µg CpG-1585, 50 µg poly-AU, 100 µg Pam3CSK4, and a 
mixture of Poly-IC +CpG-1826. On day 7 (post prime) and 19 (post boost), blood samples were 
evaluated by tetramer analysis. (b) Mice (3 per group) were immunized i.v. on days 0 and 12 with 
BiVax/CpG-1826, and boosted one more time with BiVax/ Poly-IC on day 24. The presence of 
antigen-specific CD8 T cells in blood was evaluated by tetramer analysis on days 7 (post prime), 
19 (post boost), and 31 (post 2nd boost). Points, the value for each individual mouse; horizontal 
line, the average value of the group; bars, SD. 
 
CD4 T cells may be important in the generation and long-term 
maintenance of CD8 T cell responses by functioning as helper T cells. On the 
other hand, another CD4 T cell subset known as T regulatory cells are known to 
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immunization would impact the magnitude and duration of the CD8 T cell 
response generated by BiVax with the Pam2-Trp1 peptide.  As shown in Figure 
14a, the level of the CD8 T cell response after the BiVax prime (day 6-post 
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vaccine priming) was almost 2-fold higher when CD4 T cells were depleted as 
compared to the untreated mice. The magnitude of the immune response 
increased after the booster immunization regardless of whether CD4 T cells had 
been depleted or not. Also, the duration of the Trp1 CD8 T cell response to BiVax 
was not affected by the absence of CD4 T cells during the immunizations. 
Next, using several genetically deficient mouse strains, we evaluated the 
role that various immune-related receptors could play in the generation of CD8 T 
cell responses by BiVax. The absence of CD40 and TLR3 resulted in a marked 
reduction in the levels of antigen-specific CD8 T cells observed after the vaccine 
prime (Fig. 14b). On the other hand, in the absence of IFNαβR, MDA5, and 
scavenger receptors SR-A and MARCO, the primary immune responses to BiVax 
were comparable as those observed in wild type (WT) mice.  Strong secondary 
immune responses, that more than doubled the levels of antigen-specific CD8 T 
cells as compared to the prime, were observed in all instances. However the 
absence of TLR3 resulted in severe toxicity where 3/4 vaccinated mice died by 
what appeared to be cytokine storm syndrome. In addition the fold-increase of 
the secondary response was lower in mice deficient of the MDA5 RNA helicase, 
as compared to the WT and other genetically deficient mice. Although the CD40 
and the TLR3 deficient mice exhibited lower primary CD8 T cell responses, the 
booster immunization generated strong secondary responses when considered 
as the fold-increase, compared to the primary response for each mouse strain. 
Since the adjuvant effect of Poly-IC is considered to depend in great part by its 
ability to induce high levels of type-I IFN, it was somewhat puzzling that the CD8 
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T cell responses observed in IFNαβR deficient mice were similar, if not identical 
to those observed in WT mice (Fig. 14b). However, very different results were 
observed when the minimal Trp1 peptide was used to boost the T cell response 
induced by priming with Pam2-Trp1. While as previously noted, the minimal Trp1 
peptide was efficient in boosting the responses in WT mice (Fig. 11b), this was 
not the case with the IFNαβR deficient mice where only the Pam2-Trp1 was 
capable of boosting the responses (Fig. 14c). These results indicate that type-I 
IFN may be critical only when antigen is presented by non-professional APCs, 
which occurs when the minimal peptide is used to expand the primed CD8 T 
cells. 
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Fig. 14 Immunological mechanisms involved in BiVax CD8 T cell responses.  
(a) Effect of CD4 T cells in immune responses to BiVax. Untreated or CD4 T cell depleted mice (3 
per group) were immunized i.v. on days 0 and 14 with Pam2-Trp1-Bivax (arrows), and the 
presence of antigen-specific CD8 T cells in blood were measured at various time points using 
tetramer analysis. CD4 depletion was initiated 3 and 1 d before the BiVax prime. CD4 T-cell 
depletion was confirmed by flow cytometry. (b) Role of immune receptors in the immunogenicity 
of BiVax. WT B6 mice (WT), IFNαβR-/-, CD40-/-, TLR3-/-, MDA5-/-, and scavenger receptor SR-A 
and MARCO double knockout (SR-A-/-MARCO-/-) mice were evaluated for their immune 
responses to Pam2-Trp1 7 d after prime and boost. *, 3/4 TLR3-/- mice died after the boost. (c) 
IFNαβR-/- mice were primed with Pam2-Trp1 and boosted with either the Pam2-Trp1 or the 
minimal peptide. On day 7 (post prime) and 19 (post boost), antigen-specific CD8 T cells were 
evaluated in blood by tetramer analysis. **Statistical significance (P<.01) between the 2 peptide 
responses was observed after the boost. 
 
3.4.9 Effects of the mode of administration in the immunogenicity of BiVax 
So far, the results presented above were obtained using i.v. 
Immunizations, which could be considered somewhat unconventional. Thus, we 
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compared BiVax immunogenicity using three different vaccination routes. While 
both the i.v. and i.m. routes were highly effective for the generation of strong 
responses, administration of BiVax via the s.c. route was clearly less effective 
(Fig. 15a). Lastly, we assessed whether the 2 components of BiVax, peptide and 
Poly-IC needed to be administered simultaneously, or whether separate 
injections given at different times would provide similar results.  Injecting Pam2-
Trp1 5 h before Poly-IC had no deleterious effect as compared to the 
simultaneous administration of both BiVax components (Fig. 15b). On the other 
hand, the level of the immune response was dramatically reduced when Poly-IC 
was injected 5 h prior to the administration of the Pam2-Trp1 antigen. A 
somewhat different pattern of responses was observed with BiVax using the 
HPV16-E749-57 peptide. As with the previous result, the simultaneous 
administration of peptide and Poly-IC resulted in generating the strongest 
immune response and administration of the Poly-IC before peptide reduced to a 
great extent this response (Fig. 15c). However, in this case HPV16-E749-57 
injection before Poly-IC reduced the response by ~50%. 
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Fig. 15 Effects of the mode of administration in BiVax vaccines. (a) Mice (3 per group) were 
immunized though different routes and the presence of antigen-specific CD8 T cells in blood was 
analyzed by tetramer analyses 7 d after the prime and the boost. **Statistical significance (P<.01) 
between i.v. and s.c. induced responses was observed after the boost.  *No statistical significant 
difference was observed between i.v. and i.m. after the boost. (b) Mice (3 per group) were 
pretreated i.v. with either PBS (control), Pam2-Trp1 or Poly-IC, and 5 h later received i.v. BiVax 
(Poly-IC and Pam2-Trp1) Poly-IC or Pam2-Trp1 (as indicated for each group). CD8 T cell 
responses were measured by tetramer analysis on days 7 (post prime) and 19 (post boost). (c) 
Mice were injected i.v. with PBS, E749-57, or Poly-IC and 5 h later received a second i.v. injection 
with BiVax (E749-57 + Poly-IC), Poly-IC or the E749-57 (as indicated for each group) and were 
boosted the same way 16 days later.  The percentage of tetramer positive CD8 T cells was 
determined in blood 6 days after prime and boost (n= 3 mice per group).   
 
3.5 Discussion  
There is little doubt that the effectiveness of a vaccine will depend in great 
part on its ability to elicit high levels of long-lasting antigen-specific, pathogen-
reactive CD8 T cells. Our group has proposed that these levels and the duration 
of the response should resemble those observed during acute infections [263]. 
The failure of many vaccination strategies can be attributed in many cases to the 
inability of the vaccines to generate potent and persistent immune responses. 
Other instances of vaccine failures, when strong immune responses have been 
observed, could be related to the inability of the T cells to recognize the 
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pathogen-infected or tumor cells due to low avidity of the T cells for their antigen. 
Particularly, in the case of TAAs that are also expressed by normal cells such as 
Trp1, it is likely that the highest avidity T cells are eliminated via immunological 
tolerance and that vaccines would recruit T cells of insufficient avidity to 
recognize tumor cells.  Additional concerns have been brought up on the use of 
vaccines that utilize synthetic peptides corresponding to the minimal CD8 T cell 
epitopes, including the induction of low avidity T cells due to the generation of 
supraoptimal levels of peptide/MHC-I complexes on APCs. In addition, some 
vaccines prepared with short peptide epitopes have been reported to induce T 
cell deletion [270], presumably because these peptides can be presented by non-
professional APCs. In view of this, it has been advocated that peptide vaccines 
should be prepared using long peptides that would require capture and antigen 
processing by professional APCs [239]. Indeed, when long peptides were 
administered s.c. using suboptimal adjuvants such as IFA they were found to be 
more immunogenic than their short peptide counterparts [271]. 
We present here a novel vaccination strategy called BiVax that was 
designed to mimic a viral infection, inducing high levels of CD8 T cells with 
sufficient avidity to recognize foreign and self-TAAs and capable of persisting for 
a long time period.  Our results show that a synthetic peptide corresponding to a 
minimal CD8 T cell epitope, HPV16-E749-57, mixed with Poly-IC and administered 
systemically (i.v.) in an aqueous formulation generated after a short prime-boost 
protocol (5-7 days apart), huge numbers of antigen-specific, tumor-reactive T 
cells capable of rejecting established tumors (Fig. 8). In contrast to results from 
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others obtained with vaccines administered s.c. in oil:water emulsions, the long 
peptides bearing the HPV16-E749-57 epitope were markedly less immunogenic 
than the minimal epitope, when administered using the BiVax strategy (Fig. 10). 
It remains unknown the degree of participation of professional APCs in the 
response to BiVax with the minimal HPV16-E749-57 epitope and whether non-
professional APCs could be presenting antigen to the CD8 T cells to facilitate 
clonal expansion. Also, we do not know the reason(s) why the elongated HPV 
peptides were not as effective as the short peptide in generating the vast CD8 T 
cell responses observed with BiVax.  One could assume that the large CD8 T cell 
responses observed in BiVax with HPV16-E749-57 (and hydrophobic Trp1 
peptides) require the participation of both professional APCs such as DCs (for 
the initial priming), and non-professional APCs (for facilitating clonal expansion of 
the activated T cells). Thus, the long HPV peptides would be inefficient because 
they rely solely in professional APCs, which exist at much lower frequencies than 
non-professional APCs. Our results agree with the above-stated assumption 
since a long HPV16-E7 peptide was found to be effective in priming but not 
boosting the CD8 T cell response, while the short HPV16-E7 peptide was 
effective in boosting responses induced by priming with either the short or the 
long peptide (Fig. 10). Also, the minimal Trp1 peptide was found to be inefficient 
in priming CD8 T cells (Fig. 11a) but was highly effective in expanding the T cells 
generated by the Pam2-Trp1 peptide (Fig. 11b). Nevertheless, the ability of the 
Pam2-Trp1 and elongated hydrophobic Trp1 peptide constructs not only to 
effectively prime the CD8 T cells, but also to successfully expand these 
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responses needs to be addressed since these peptides presumably would 
require to be presented by non-professional APCs. The possibility exists that 
lipidated and hydrophobic elongated peptides may be able to be captured and 
undergo processing by both professional and non-professional APCs, while other 
long, not-so-hydrophobic peptides such as HPV16-E745-57 and HPV16-E743-77 
may not be so effective in being captured by non-professional APCs. The 
possibility also exists that short peptides such as HPV16-E749-57 and elongated 
hydrophobic Trp1 peptides may form complexes with Poly-IC, which are more 
effectively internalized by APCs via some type of nucleic acid-binding scavenger 
receptor (SR). Once inside of the cell, the peptide/ Poly-IC complexes within 
endosomal compartments will stimulate TLR3 and may spill the contents to the 
cytoplasm due to the proton sponge effect generated by the endosomal nucleic 
acid content. Although all these possibilities remain to be studied, the necessity 
for the formation of peptide/ Poly-IC complexes is somewhat supported by the 
observations that administration of Poly-IC prior to the peptide did not lead to the 
generation of the strong immune responses (Fig 15b-c).  One would expect that 
Poly-IC would quickly be cleared from circulation by binding to the numerous 
SRs whose function is to rapidly eliminate foreign and self-free nucleic acids. The 
injection of the peptide before Poly-IC could work if the persistence of the peptide 
in circulation allows the in vivo formation of complexes with Poly-IC.  Members of 
the SR class A (SR-A) family are known to bind nucleic acids. Our results 
indicate that BiVax generated levels of CD8 T cells in mice deficient in SR-AI/II/III 
and MARCO that were equivalent to those observed in WT mice. Thus, it is likely 
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that other class of SRs may be capable of interacting with Poly-IC. The 
redundancy in the specificity of SRs makes it difficult to pinpoint exactly those 
receptors in professional and non-professional APCs that would be involved in 
the capture of peptide/ Poly-IC complexes. 
With respect to the differences observed with the various routes of 
administration, we initially reasoned that a systemic administration (i.v.) of the 
vaccine would be able to deliver antigen throughout most lymphoid organs 
recruiting larger numbers of antigen-specific T cells as compared to a local (s.c.) 
immunization, where only draining lymph nodes would be involved. Indeed, 
BiVax given i.v. was far superior as compared to BiVax s.c. (Fig. 15a). 
Interestingly, BiVax i.m. was as effective as BiVax i.v.. Thus, it is possible that 
the peptide, Poly-IC mixture (or complexes) can effectively diffuse from the 
muscle into the general circulation to reach proximal and distal lymphoid organs. 
It has been advocated that most vaccines should be administered i.m. and not 
s.c. because of higher vascularity of the muscle as compared to the 
subcutaneous fat layers, which will influence antigen diffusion into the 
bloodstream [272]. 
Poly-IC has been considered to function as a potent immune adjuvant due 
to its ability to stimulate endosomal TLR3 and cytoplasmic retinoic acid-inducible 
gene (RIG)-1-like receptor (RLR) family member, MDA5. As a result of TLR3 and 
MDA5 activation, cells produce high amounts of IFN-I and other proinflammatory 
cytokines such as IL-1, TNFα, IL-6 and IL-12. Our results showed that the levels 
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of immune responses induced by BiVax were lower in mice deficient for either 
TLR3 or MDA5 as compared to WT mice (Fig. 14b). The levels of CD8 T cells 
induced after priming were substantially lower in TLR3-KO but not in MDA5-KO 
as compared to the WT mice. On the other hand, the fold-increase in the level of 
the immune response observed in MDA5-KO was decreased as compared to 
what was observed in WT mice. There was some indication that the secondary 
response induced by booster immunization in TLR3-KO mice was effective, as 
evident by the large difference between primary and secondary responses, but 
this could only be verified in 1/4 mice because of severe toxicity of the vaccine in 
these mice.  Mice deficient in CD40 responded poorly to the primary 
immunization but exhibited a large secondary response after the booster. Putting 
together all of these results, one could speculate that during the primary immune 
response in which professional APCs may play a more critical role, that TLR3 
activation and CD40 costimulation play an important role in the activation of the 
naïve T cells. On the other hand, during the secondary response, the stimulation 
of the previously activated T cells can be effectively carried out by non-
professional APCs that are activated by Poly-IC mostly through MDA5 and that 
do not require the participation of TLR3 and CD40.  
The elimination of CD4 T cells resulted in an increased primary CD8 T cell 
response as compared to the normal mice controls. These results suggest the 
possible elimination of a CD4 T regulatory cell population that somewhat 
decreases the effectiveness of priming with BiVax. More importantly, the results 
demonstrating that CD40 was required for effective priming, suggest that other 
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cells besides CD4 T cells that express CD40L (CD154) such as platelets, 
granulocytes, subsets of CD8 or gamma-delta T cells may function as helpers 
during the BiVax primary response.  As mentioned above, Poly-IC is known to 
induce the production of high levels of IFN-I, which has been demonstrated to 
function as “signal 3” for the activation and expansion of CD8 T cells [273]. In 
view of this, we assumed that the adjuvant effect of Poly-IC in BiVax could be 
due to the signal 3 effects of IFN-I on the peptide-stimulated CD8 T cells. Thus, 
we were surprised that BiVax using Pam2-Trp1 functioned well in IFNαβR 
deficient mice (Fig. 14b), indicating that IFN-I signals are not critical for the 
activation and expansion of CD8 T cells in this vaccination strategy. Interestingly, 
in contrast to what was observed in WT mice, that the minimal Trp1 peptide was 
effective in boosting the CD8 T cell responses of Pam2-Trp1 primed mice (Fig. 
11b), in IFNαβR deficient mice only the Pam2-Trp1 was able to boost while the 
minimal Trp1 peptide did not (Fig. 14c). These findings suggest that IFN-I may 
play a critical role when non-professional APCs present antigen during the 
expansion phase to the previously activated CD8 T cells. Thus, IFN-I may serve 
as an endogenous danger signal that would allow proliferation of T cells to 
antigens presented by infected cells that are not professional APCs. On the other 
hand, T cells activated by professional APCs reactive to self-antigens, when 
presented by antigen by non-professional APCs in the absence of IFN-I would 
not continue to proliferate, limiting an autoimmune response. These results 
indicate that Poly-IC stimulation of professional APCs results in a TLR3/CD40-
dependent and IFN-I/MDA5-independent primary activation of CD8 T cells where 
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alternative cytokines such as IL2, IL12 and IL15 may serve as signal 3 leading to 
activation and an initial somewhat restrained clonal T cell expansion. However, 
soon after (5-7 days) the initial activation of the CD8 T cells by professional 
APCs when non-professional APCs present antigen to the T cells in 
circumstances where IFN-I is being produced via MDA5 stimulation by Poly-IC 
(or viral dsRNA), a massive T cell expansion will be generated.  We believe that 
many of vaccines designed to elicit CD8 T cell responses such as peptide (long 
or short) vaccines formulated in IFA, peptide-pulsed DCs and plasmid DNA 
immunization are probably effective in accomplishing the primary T cell activation 
and initial limited T cell expansion but fail to induce the secondary massive T cell 
expansion, observed in natural immune responses during acute infections, which 
may be necessary to obtain effective anti-tumor effects. In contrast, BiVax using 
amphiphilic peptides and Poly-IC is highly effective in both the priming 
(activation/initial expansion) and massive expansion after the secondary 
immunization.  
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Chapter 4: General Conclusions 
 
The results of my doctoral work show that immunization with a synthetic 
peptide representing an exact CD8 T-cell epitope from the HPV 16 E7 protein in 
combination with Poly-IC (BiVax) and αCD40 mAb (TriVax) resulted in extensive 
antigen-specific T-cell responses that were durable and capable of eradicating 
established tumors. In addition, TriVax generates immunological memory that 
prevents tumor recurrences and although the optimal route of administration is 
the i.v. route, the i.m. route was almost as effective (it generated less number of 
tetramer cells and recurrence 1/6 of mice). TriVax mechanism of action is CD8 T 
cell dependent and IFNγ and type I IFN absence had little effect in early stages of 
tumor growth control. Interestingly, while one single TriVax vaccination induces 
tumor clearance in 100% mice, 2 vaccinations with BiVax induce clearance in 
just 50% of mice. These differential effects are due to the quantity of antigen 
specific CD8 T cells generated after vaccination and additional BiVax boosters 
improved vaccine immunogenicity and correlated with enhance anti tumor effect 
generating clearance of tumor in all vaccinated mice.  
In the search for improved immunogenicity we tested several HPV 
peptides including modification of the E749-57 (minimal peptide) and extensions of 
the minimal peptide (HPV16-E745-57 and HPV16-E743-77); none of the peptide 
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assayed surpasses the minimal peptide immunogenicity in BiVax’s formulation. 
The results showed that BiVax can be used in the context of other TAAs (Trp2), 
furthermore the immunogenicity of peptides in the BiVax formulation can be 
enhanced by generating an amphiphilic construct, such improvement in 
immunogenicity correlated with enhanced antitumor effect. BiVax anti tumor 
effect was CD8 dependent and CD4 depletion affected priming with amphiphilic 
Pam2-Trp1 but not the response after boost and duration of the immune 
response. In addition, the absence of CD40 and TLR3 resulted in a marked 
reduction in the levels of antigen-specific CD8 T cells observed after the prime 
with BiVax. And while both the i.v. and i.m. routes were highly effective for the 
generation of strong responses, administration of BiVax via the s.c. route was 
clearly less effective. Finally, BiVax’s components have to be administrated 
simultaneously to obtain optimal immune response, interestingly administration of 
Poly IC 5 hours before the administration of the peptide (but not the other way 
around) reduces immunogenicity considerably. 
The results of the work shown here indicate that the TriVax and BiVax 
strategies are appealing immunotherapeutic approaches for the treatment of 
established viral-induced tumors. We believe that these studies may help to 
launch more effective and less invasive therapeutic vaccines for HPV-mediated 
malignancies. 
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